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PREFACE
 
The Final Report on Phase Ill of the Study for Identification of Beneficial Uses of Space 
(B. U. S.) is comprised of three volumes: 
Volume I Executive Summary 
Volume II Technical Report 
Volume III Appendices 
Volume II is further subdivided: 
Book 1 - Development and Business Analysis of Space Processed Isoenzymes 
Book 2 - Development and Business Analysis of Space Processed Transparent Oxides 
Book 3 - Development and Business Analysis of Space Processed Tungsten X-ray Targets 
Book 4 - Development and Business Analysis of Spa6e Processed Surface Acoustic 
Wave Devices 
Book 5 - Study Methods and Trade Studies 
General Electric's Space Division, under contract from the NASA's Marshall Space 
Flight Center completed Phase I of the Study in December 1972, and Phase II in Decem­
ber 1973. In Phase II, the Study has progressed to the Business Analysis and Planning 
for the commercial development and production of the four products in Phase 11: 
* Surface Acoustic Wave Components 
* Transparent Oxides 
* High Purity Tungsten X-ray Targets 
* High Specificity Isoenzymes 
The methodology employed in the Phase II Study and the results of that effort are re­
ported herein. 
In addition to Key Individuals from the participating User organizations who contributed 
specific product, process, business and planning data in each of their respective areas, 
iii 
the Study Manager acknowledges the outstanding financial and manufacturing analysis 
contributions of Mr. P. Schmitt, and the considerab~e contributions of the following: 
Mr. U. Alvarado and Mr. M. Clarke of the Study Team in analyzing and organizing the 
wealth of data-accumulated; oMr. K. Taylor, the MSFC Contracting-Officers Represen­
tative (C. 0. R.) for the study, in providing key technical suggestions and direction to 
the overall effort as well as establishing space processing payload guidelines, Mr. G. 
Wouch, Dr. E. Okress, and Dr. B. Noval of General Electric's Space Sciences Labora­
tory, in providing supporting space processing data, and Mr. B. Klawans and Mr. F. 
Curran of General Electric's Systems Operation and Computations Component in pro­
gramming and processing "INVEST", the interactive profitability analysis program. 
As noted in the Final Reports of earlier Phases, publication of this Phase IIl report 
neither implies NASA endorsement of any specific product, process or venture identi­
fied during this phase of the Study, nor a NASA commitment to pursue any program de­
fined as part of this Study. 
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SECTION I
 
INTRODUCTION
 
This volume comprises preliminary development plans, analysis of required R & D 
and production resources, the costs of such resources, and, finally, the potential 
profitability of a commercial space processing opportunity for electrophoretic separa­
tion of high specificity isoenzymes. The work reported herein is a continuation of 
investigations into the space processing of isoenzymes which have been conducted in 
Phases I and II of NASA Study Contract NAS 8-28179 (1971-1973). 
Technical Support for these investigations has been provided by Polysciences, Inc. 
of Warrington, Pennsylvania, primarily by 
Dr. B. Halpern, President 
Dr. S. Ledis 
Dr. S. Greenfield 
The baselines selected for development planning are conceptual, and were established 
to provide a means of assessing overall technical and economic feasibility under con­
ditions of limited experimental space processing information and very long range 
market, space facility, and cost projections. These baselines can be expected to 
change, perhaps even drastically, as later analytical and experimental investigations 
continue. 
I.1 BACKGROUND 
At present there are nearly 2000 identified enzymes, of which about 100 are Imown 
to have isoenzyme forms. Isoenzymes are alternate forms of enzymes (biological 
I-i 
catalysts) which exist in slightly different molecular forms. We have previously(1 ) 
noted the known, and possible, relationships of isoenzymes to certain diseases and 
organic damage, and the possibilities of utilizing high specificity separations of certain 
isoenzymes in the early diagnosis of some of these afflictions. However, the forces 
which stabilize the various structural levels of isoenzymes are extremely weak, and, 
during separation, are easily disturbed by heat, chemical agents, and strong electrical 
potentials, as can occur in conventional electrophoresis at high voltage gradients 
('10 v/cm). These conditions cause distortion of the enzyme structure (denaturiza­
tion), which results in the loss of enzyme activity. What is needed, therefore, is a 
"gentle" separation technique. 
The most commonly and successfully employed ground-based isolation techniques for 
isoenzymes has been conventional small pore gel eleotrophoresis. Increased resolv­
ing power of separation, while maintaining low ohmic heating and low electrical poten­
tials, is expected from proven techniques using large pore gels and/or isoelectric 
focusing in the "zero gravity" of orbital flight, where longer separation paths aid 
resolution and low voltage gradients minimize denaturization. 
As pointed out in Reference 1, our goal in this area of Space Processing is the develop­
ment of a separation method to provide reasonable yields of high specificity isoenzymes 
for the purpose of large scale, early clinical diagnosis of diseases and organic damage 
such as, possibly, myocardial infarction, hepatoma, muscular dystrophy, renal 
disease, nervous system disorders, cerebral infarction, other cancers, glycogen 
storage disease, and infectious disorders. 
(1)STUDY FOR IDENTIFICATION OF BENEFICIAL USES OF SPACE (PHASE 1) 
NASS-28179, Final Report, GE Document #73SD4259, December 10, 1972 and
 
April 23, 1973.
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1.2 	 ASSUMPTIONS 
In addition to the basic Study Assumptions reviewed in Section IV of Volume I, the 
following key assumptions have been made in the development planning: 
* 	 The experiments and tests, defined in Phase II and updated in this Phase, 
will result in a successful technique for separating preparative amounts of 
higher specificity, undenatured isoenzymes through large-pore gel electro­
phoresis of enzymes in space. Other useful macromolecules will also be 
beneficially separable through use of the same techniques, and possibly, 
the same equipment model. 
* 	 Separated isoenzymes will be used primarily in diagnostic, as opposed to 
therapeutic, procedures, although the latter application may well offer even 
greater benefits in the future. 
* 	 An initial Study Guideline (Section IV. 1, Volume I) directed that our pro­
fitability analysis assume that each User bear the full cost of developing 
the Space Process utilized for producing his product. All four of the prod­
ucts under study were unattractive ventures under the combination of this 
assumption and derived economic data. The NASA C.0.E. suggested that 
this combination be noted as "Case A". 
He further suggested that, since basic processes would have broader applica­
tion than the individual products under study, it could likely be assumed that 
basic process proof-of-feasibility would be carried out under government 
funding. Users, therefore, would only bear those R&D costs that specifically 
provide prototype/pilot plant capability. The combination of this assumption 
and the same derived economic data as in the prior case is called "Case B". 
1.3 	 PRODUCT OBJECTIVES 
The 	primary product objective for isoenzymes is to utilize the "zero gravity" of the 
space environment to produce, via high specificity electrophoretic separation from 
sera, tissues, blood, etc., specific isoenzymes (which are present in disease or 
damage states) without denaturization. 
1-3 
The secondary product objective is to use the high specificity isoenzymes to create 
antibodies and market them to pharmaceutical companies, hospitals, clinics and 
physicians for use in diagnostic procedures. This objective requires the development 
of a process sufficient to deliver-the high specificity isoenzyme products on a prepara­
tive scale (several thousand milligram annual throughput). 
Isoenzymes of most immediate interest are creatlne kinase and glycogen phosphoryl­
ase, although many others would be produced when, and if, the process becomes 
available. 
.4 PROCESS ALTERNATIVES AND BASELINE
 
The alternative process methods and key steps in the baseline approach selected for
 
this Phase of Study have been derived in Phase 11. These are shown in Figure I-1.
 
Those major alternatives and decisions left unresolved in Phase II, due to lack of
 
critical phenomenological or process data, have, for the most part, been resolved
 
by assumption for purposes of this phase of study. It must be noted, however, that
 
a high degree of judgement has been exercised in making the required selection.
 
The technical decisions and unknowns associated with this selection are given in 
Figure 1-2. 
The unknowns listed in Figure 1-2 are those which form the basis for the subsequent 
definition of experiment and test Work Elements in the R&D portion of the Work Break­
down Structure. It is recognized that current Space Processing programs are address­
ing such unknowns as macromolecule mobility relationships to resolution, and effective­
ness of isoelectric focussing, etc. Resolution of any such unknowns through current 
or other future programs are not accounted for here, but will, of course, influence 
the future application of this study's findings. 
Baseline process data defining key requirements for the selected process are shown
 
in Section 11. 2.5.
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Decisions 
1. Choice of gel composition, density, etc. 
2. 	 Choice of forming and loading gel prior 
to launch or in space 
3. Selection of Buffer System 
4. Selection of Running Conditions 
5. Selection of Separation Method 
6. Selection of Isolation Method 
7. Choice of Preliminary Separation method 
8. 	 Choice of Preliminary Preservation 
method 
Current Preferred 
Method 
large pore gel 
prior to launch 
Discontinuous 
batch process, small 
quantities 
gel electrophoresis/ 
isoelectric focussing 
freeze 	gels 
ammonium sulphate 
precipitation, 
colunmchromatography, 
& dialysis 
lyophilization 
Unknowns* Which Reqmre Experiments and Tests for Resolution 
1. Dissolving gel possibilities and characteristics. 
2. Loss of isolation/resolution in frozen storage. 
3. Migration of components under the influence of weak forces. 
4. Ability of gel, etc., to withstand launch forces (g's & vibration). 
5. Electrophoresis process stability at less than 10 volts/cm. 
6. Effects of voltage gradient on enzyme mobility. 
7. Relationship of enzyme mobility to resolution. 
8. Ohmic heating rates in gels. 
9. Convection rates in enzyme bands in gels. 
10. Effects of electrophoresis path length on resolution of isoenzymes. 
11. 	 Relative effectiveness of large- and small-pore gel electrophoresis and 
isoelectric focussing. 
12. 	 Effects on total process of variations in buffers, gel types, running time, 
voltage gradient, etc. 
Figure 1-2. Current Decisions and Unknowns* 
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SECTION II 
DEVELOPMENT PROGRAM 
The framework upon which development tasks, schedules, costs, equipment and 
facility needs, etc. are constructed, is the Work Breakdown Structure (WBS). 
While relatively unfamiliar outside the Aerospace/Military communities, it is felt 
to provide sufficiently valuable insight to program planning to warrant its introduc­
tion into this commercial product study. 
We have, however, deviated from the usual WBS content. The long development 
effort for products under study, the need for both Space and Ground Processing steps, 
the obvious comparisons between familiar ground processes and the "new" Space­
involving process led us to establish a WES based on process steps, rather than on 
equipment. Thus, subsequent analyses could easily compare value added versus cost 
added for any process step. 
This section of the report details the WBS for the Isoenzyme processing program and 
summarizes the Work Element Descriptions, Work Element Resource Requirements, 
and Resource costs. Finally, it assembles the Development Schedule. 
11. 1 WORK BREAKDOWN STRUCTURE 
The Work Breakdown Structure against which the development and production tasks 
are organized is shown in Figure II-1 A&B. Figure II-lA depicts the configuration of 
the WBS at the top level, while I-lB delineates the detailed structure. The develop­
ment effort which is documented in over 120 pages of work element descriptions, work 
element resource needs and resource costs, is summarized in Section 11. 2. 
The technical and business assessment of the in-space isoenzyme separation oppor­
tunity requires that all elements of work, from raw materials to finished product be 
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Figure U1-1A. Work Breakdown Structure for Isoenzyme Processing 
examined, costed and analyzed. The major process steps of the WBS provide a 
,suitable framework for collecting tasks and costs over that sequence of events, 
and this approach tends to assure that no major business costs are overlooked. 
Three major process steps are.defined for isoenzymes: 
Gel Preparation (WBS 4. 0)
 
Isoenzyme Separation (WBS 5. 0)
 
Isoenzyme/Antibody Preparation (WBS 6.0)
 
In addition, work elements for integrating and planning the development and pilot/ 
production program are added as follows: 
Program Management (WBS 1. 0)
 
System Engineering (WBS 2.0)
 
Business Operations (WBS 3. 0)
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1.0 Program Management 
1. 1 Program Management - R&D 
1.2 Program Management - Pilot/Production
 
2.0 System Engineering
 
2.1 System Engineering - R&D
 
2.2 System Engineering - Pilot/Production
 
3.0 Business Operations
 
3. 1 Business Operations - R&D 
3.2 Business Operations - Pilot/Production
 
4.0 Gel Preparation Process Step
 
4.1 Gel Preparation Process Step - R&D
 
4. 1. 1 Process Development 
4.1.1.1 Project Supervision
 
4. 1. 1.2 Ground Lab Tests 
4.1. 1,.2.1 Launch Environment Testing of Gels (Test HIB)*
 
4. 1. 1.2.2 Storage of Prerun samples w/o Denaturation (Test IIIC)* 
4. 1. 2 Gel Preparation Equipment Development 
4.2 Gel Preparation Process Step - Pilot/Production
 
5.0 Isoenzyme Separation Process (in-space)
 
5.1 Isoenzyme Separation Process - R&D
 
5. 1,1 Process Development 
5.1.1.1 Project Supervision
 
5.1.1.2 Ground Lab Tests
 
5.1 1.2. 1 Enzyme Mobilities vs Voltage Gradient low V, Test IA*
 
5.1.1.2.2 Effects of Convective Disturbance on Resolution (Test IB)*
 
5.1. 1.2.3 Use of Long Path Length to Improve Separatfon (Test IC)*
 
5.1.1 2.4 Gel Length vs Resolution - Isoelectric Focusing (Test ID)*
 
5.1. 1.2.5 Best Ground Method of Separation (Test IIA)*
 
5.1.1.2.6 Preparative Scale Separation Tests (Test IIB)*
 
5.1.1.2.7 Environmental Tests on Standard Equipment (Test IIIA)*
 
5.1.1.3 Sounding Rocket Tests
 
5.1. 1.3.1 Separator Design & Test (Part of Test IV)*
 
5 1. 1.3.2 Freezer Design & Test (Part of Test IV B)* 
5.1 1.3.3 Power Unit Design & Test (part of Test IVC)*
 
5.1.1.4 Shuttle/Spacelab Tests
 
5.1.1 4.1 Separator Tests (part of Test IVA)*
 
5.1.1.4.2 Freezer Tests (part of Test IVB)*
 
5.1.1.4.3 Power Unit Tests (part of Test IVC)*
 
5.1.1.4.4 Prototype System Test (Test VA, B, C)*
 
5.1.2 Equipment Development
 
5.2 Isoenzyme Separation Process - Pilot/Production
 
6.0 Isoenzyme/Antibody Preparation
 
6.1 Isoenzyme/Antibody Preparation - R&D
 
6 1. 1 Process Development 
6.1.1.1 Project Supervision
 
6.1.1.2 Ground Lab Tests
 
6.1. 1.2.1 Post Separation Isoenzyme Storage Effects (Test IUD)*
 
6.1.1.2.2 Efficacy of Antibodies
 
6.1.2 Equipment Development
 
6.2 Isoenzyme/Antibody Preparation - Pilot/Production
 
*Test Numbers Refer to Tests Identified in Phase II 
Figure II-1B. Isoenzyme Work Breakdown Structure Details 
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Each WBS element above is divided into R&D and Pilot/Production phases, with the 
R&D phase ending at completion of a prototype capability. Work and cost summaries 
can thus be obtained either for a process step or for a particular phase. The ability 
to summarize a process step facilitates comparison of the cost of a process relative 
to others, assessment of alternatives (e. g. buying of prepared gel tubes rather than 
in-house preparation), the examination of value added in each process step and 
examination of the option to sell as a product, the output of a particular process step. 
Within each process, work is subdivided as to whether it is Process Development 
(requirements, system design, subsystem and system tests) or Equipment Develop­
ment (component design and test based on process development requirements). Hard­
ware breakdown as used in aerospace Work Breakdown Structures occurs as a lower 
level of Equipment Development. 
11. 2 WORK ELEMENTS (WORK TO BE DONE)
 
The development of a ground/space/ground process sequence such as that in Figure 11-2
 
for separation of high specificity isoenzymes can be summarized into the following top
 
level Work Elements:
 
1.0 Program Management 
2.0 System Engineering 
3,0 Business Operations 
4.0 Gel Preparation Process Step (ground) 
5.0 Isoenzyme Separation Process Steps (in-space) 
6.0 Isoenzyme/Antibody Preparation Process Step (ground) 
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Figure 11-2. Isoenzyme Processing Ground/Space Process Steps and Facilities 
These elements apply to both the development (R&D) phase and pilot plant and pro­
duction phases. The R&D effort for Isoenzyme production is largely concentrated 
in the in-space process step (WBS 5.0) and this development plan accordingly empha­
sizes that area of work. However, many development activities involve the active 
participation and close coordination of multiple Work Elements. Typically, the 
development program includes a series of major experiments and tests shown in 
Figure Il-3A from which the sounding rocket and shuttle tests are further summarized 
in Figure I-3B. In all cases, there is exhibited a high degree of combined Work 
Element involvement. A description of the work to be done in each element is given 
in the following paragraphs. 
U1. 2.1 PROGRAM MANAGEMENT (WBS 1. 0) 
Program Management in the R&D phase will include the definition of development 
tasks and schedules, arranging for and controlling the resources needed, and main­
taining a management liaison with the parties involved. These parties will include the 
I-5 
WBS 
IA - Enzyme mobility vs. Voltage Gradient at low gradients 5.1.1.2.1 
Ground Lab - Electrophoresis 
0 IB -Convection creteffects onIonyeband resolution 51.1.2.2 
0 
~ Ground Lab - Electrophoresis
IC - Effect of Long Path Length on Isoenzyme Separation 5.1.1.2.3 
o TGround Lab - Electrophoresis
 
i P ID - Effect of Long Path Length on Isoenzyme Separation 5.1.1.2.4
 
1 Ground Lab - Isoelectric focussing
 
d IIA - Best ground method of Separation 5.1.1.2.5 
• 4 Ground Lab - Etlectrophoresis{IIB - Best scale-up method for Isoenzyme Separation 5.1.1.2.6 
Ground Lab - Preparative-scale separator 
IIlA - Launch environment effects on standard equipment 5.1.1.2.7 
Ground Environ Test Lab - Electrophoresis 
IIIB - Launch environment effects on Gels 4.1.1.2.1 
Ground Environ Test Lab 
0.4 1110 - ]Denaturation effects of Sample storage 4.1.1.2.2> Ground Lab
 
P N IID - Post-separation Isoenzyme storage effects 6. 1. 1.2.1 
Ground Lab
 
IVA - Design test of Separator unit for space operation 5.1.1.3.1/5.1.1.4.1 
O qKC-135, Sounding Rocket, Shuttle 
S IVB - Design test of Freezer Unit for space operation 5.1.1.3.2/5.1.1.4.2 
KC-135, Shuttle 
> aZ0 W IVC - Design test Electrical Power Unit for space operation 5.1.1.3.3/5.1.1.4.3 
KC-135, Shuttle 
A, B, C Proof test complete Separation System (Prototype) Space 5.1.1.4.4 
Shuttle Laboratory Module. 
P4 PVI Efficacy of Antibodies 6.1.1.2.2 
Ground Lab 
Figure i-3A. Isoenzyme Test Series 
WBS 
No Test 
Experiment 
No 
Power 
Req'd 
(KW) 
Experiment 
Weight 
(Kg) 
Experiment 
Vol 
(M3 ) 
Flight 
Date 
(Yr) 
Total 
Experiment 
Duration 
Flight 
Crew 
Support 
Req'd 
Flight 
Vehicle 
Data 
Transmission 
Requirements 
Data 
Processing 
Requirements 
Energy 
Requirements 
(KWEi 
51 131 Separator Test IVA 03 100 03 78 10 mm no S/R-1 TED N/A 01 
51131 Separator Test IVA 03 100 03 79 10mm no S/R 2 TBD N/A 01 
511 32 Freezer Test IVB 03 30 02 78 40-100 runs 
30 actseach 
yes KC-135 TED N/A 01 
51 14 1 Separator Test IVA 03 200 05 80 7 days 14 man hrs Shuttle SL-1 - none none 30 KWH 
5 11 4 1 Separator Test IVA 03 200 05 81 7 days 14 man hrs Shuttle SL-2 none none 50 KWH 
5 1142 Prototype/Proof Test V 05 200 05 82 7 days 14 man hrs Shuttle SL 3 none none 85 KWH 
5 1 4 2 Prototype/Proof Test V 0 5 200 0 5 83 7 days 14 man hrs Shuttle SL-4 none none 85 KWH 
Figure I-3B. Sounding Rocket and Shuttle Flight Test Requirements 
pharmaceutical research laboratory, product manufacturer, NASA centers, the space 
system contractor, and NASA contractors. While each development task will include 
project supervision of that work, Program Management will provide for the overall 
management of all aspects of the program. The three Work Elements in WBS 1. 0 
include resource needs for reports, presentations, special documents and plans. 
Key outside consultation has also been included in Program Management in response 
to Polysciences' request. When the production phase becomes routine, Program 
Management is planned to phase out and the planning and control activities are to be 
handled by administrative and production control functions of the business. Some 
project engineering services will be required to handle shuttle services and interfaces. 
. 2.2 SYSTEM ENGINEERING (WBS 2.0) 
In the R&D phase, System Engineering will be required to establish requirements and 
specifications for design of overall ground-space-ground process sequence and to 
conduct tests of overall processes. As development tests eliminate the present un­
knowns and technology gaps, System Engineering will convert these findings to a 
specific prototype system design (ground-space) and ultimately to a pilot/production 
mission profile as portrayed in Figure 11-4. In commercial terms, this is a combined 
plant engineering and product engineering activity, with the added dimensions of space 
vehicle/payload interfacing and orbital operations requirements. The outputs of the 
R&D System Engineering effort will be overall process and materials specifications 
and process equipment design requirements. In the routine production phase, System 
Engineering phase out and is replaced by Advanced Engineering. The three Work Ele­
ment descriptions under System Engineering provide for such resource needs as 
computer services and equipment test facilities. 
11. 2.3 BUSINESS OPERATIONS (WBS 3.0) 
Business Operations in the R&D phase will be concerned with business preparations 
is anticipation of a successful development effort and initiation of production. Business 
planning must be done continuously as a basis for investment decisions as R&D results 
are obtained. Three areas of business operations are described as follows: 
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Figure 11-4. Isoenzymes Production - Development and Mission Profile 
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WBS 3. 1. 1 MARKETING 
Development program initiation is necessarily based on very early estimates of 
business viability and financial returns. During the R&D activity, Marketing must 
continuously analyze the potential market, market share, anticipated orders, product 
offerings, gross margins, product costs, profits, etc. in order to confirm or modify 
earlier plans. As the time of pilot production approaches, Marketing will prepare 
sales literature, preliminary catalog data, and price data as the basis for customer 
contact. The product distribution system will be designed and an appropriate sales 
organization will be initiated. Demonstrations of product characteristics and per­
formance will be conducted using samples from early tests and prototype/pilot runs 
to convince customers of product advantages and to establish a preliminary seller/ 
purchaser understanding. Advance orders will be solicited, as early as possible in 
the R&D phase to reduce the risk associated with a commitment to build production 
facilities. When the production phase begins, Marketing will conduct routine order 
processing, cataloging, product service, product planning, and sales engineering 
activities as well as future market/business planning. 
WBS 3.1.2 ADVANCED ENGINEERING 
Advanced Engineering will be relatively quiescent during the R&D phase since the 
R&D System Engineering and R&D Experiment and Test tasks will be accomplishing 
that function. A limited amount of second generation technical investigation will be 
done to explore opportunities which lie beyond the scope of the R&D effort. These 
findings may have an effect on the direction of the R&D effort. When the production 
phase begins, Advanced Engineering work wilt increase to develop improvements on 
the pilot/production design and to introduce new processes and facilities as suggested 
by Marketing plans. 
WBS 3.1.3 FINANCIAL, LEGAL & RELATIONS SUPPORT 
In the R&D phase, the Finance, Legal, & Relations functions will participate with 
Marketing in the preparation and critique of business plans, and recommending of 
n-10 
steps to be taken by management to prepare for production. The timing and amount 
of investments will be critical, with pressures to move quickly to establish a market 
position, and concurrent pressures to postpone action, to reduce financial risk. 
Relations will be concerned with staffing of R&D positions and planning for production 
staff. Legal will address the contract/subcontract terms anticipated for production 
and the insurance/indemnity/warranty provisions that are planned to be used. This 
work will include establishing of the terms for using NASA Shuttle and other space 
facility services, as well as defining the associated manufacturer/NASA liabilities. 
H. 2.4 GEL PREPARATION PROCESS STEP (WBS 4.0) 
The R&D effort on this step of Isoenzyme production is comprised of 8 Work Elements 
which will examine the basic phenomenology of gel types, gel constraint methods, 
ground environmental influences and storage effects, to arrive at a gel tube which is 
appropriate for space processing. The effort will attempt to define the specific gel 
type (composition, density) among a number of alternatives, the gel tube characteristics, 
including tube plugging or other closure methods, and the proper handling and prepara­
tion methods to be used. A series of ground tests such as indicated in Figure II-5A 
will be conducted for this purpose. In addition, the selected gel products will be used 
in WBS 5.0 Work Elements for subsequent in-space testing. The question of gel life 
in storage will be answered by a series of storage tests followed by examination of 
gel condition. The gel preparation process will be affected by the results of in-space 
tests, in that the success or lack of success in use of gel tubes of various lengths, 
diameters, capping methods, etc. will confirm or require modification of the gel 
preparation techniques. The effects of launch forces on gel tube packaging must also 
be examined as noted in Figure I-5B. The test series will attempt to fill the 
knowledge gaps and establish a prototype gel preparation process, starting with ex­
perimental quantities and expanding to preparative-scale quantities. 
In the pilot/production phase, scale-up of prototype designs is expected to be feasible 
without encountering major development questions. That is, scale-up should be possi­
ble by merely increasing the throughput of an already established tube configuration 
and gel type. 
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~A 	 EXPERIMENTS TO VERIFY SELECTED APPROACH FOR SEPARATION OF ISOENZYMES 
S FACl LITY EXPERIMENTS AND VERI FICATION TESTS 	 OBJECTIVES EXPERIMENT AND TEST REQUIREMENTS (SUMMARY) 
GROUND LAB 	 Tests of specific enzymes in various gels at Relationship of enzyme mobility in gels to voltage Standard ground'tab, standard efectrophorette separator 
specific voltage gradients, and on aclosely gradient (gradients < 10 V CM) and relationship of (typically, Hoeffer DEIO?) and peripherals, controlled 
spaced set of isoenzymes at established mobility mobility to isoenzyme resolution voltage gradients (< 1eV/CM) isoenzyme sets (Esterases,
Alkaline Phosphetases, Hexosammrdases) photographic and 
measurement equipment, analytical staining apparatus, 
10-15 hours per run Manual loading, initiation, adjust­
ments, termination, sample transfer, automated running. 
Tests using small temperature sensors in gel Measurement of local heating within agel during Standard ground lab, equipment as above plus controllable 
during electrophbresis at various voltage electrophoresis and rate of convective distur. (1020") heaters tailored to electrophoreis tubes, thermo-, 
gradients to determine heating and convective bance of enzyme bands in gels 	 couples in gel, 2 days per runeffects on separated bands 
Testona 1e1sc of isoe fltat ath tngotor s smdiedsi e , spaed set iYns it various io ip ofpnl "sutlnof nsoenr t o ndterdlb, adarde licnro reict p o in 
I,ppeatsd,redsints, .letd ionaymo ny$i., snyiptoal 1an oEXPERMENT TobVERIFYr 	 S ndr u 'mlUZ, Sd u= eerportnseaao
- ....
and au mnm I d~yltrun MaurrodI 

Standard ground lab, standard electroporeic separatorTests of several specific isoenzyme systems to Best separation method (initially, modified or new later), equipment to carryand smal poregl and =oelectric
compare large focusin sytem, vryin ge tyesout bufer large and small poe eleotrophortessaseral gels) 
soeletaric focussing vanous buffers, voltage rgulaon n 
tcphotographic 	 equipment, analytical runingtie, olagegraiet, 	 and measurement sann 
opoo t pp D s,n roManualofand automated tasks asap aratus, 1day per ru  
Tctofuprivaiiveoddiioey 	 for, olpes r aioo prciorvaion of peinmns-prollund godo u loodiiyo ph (connroiiabSlEoylroncntaichmbqrlaeosinenperaor tpr 
and evirondents et Viions p i feandvaooiuLbuohfers,aii buffered refruatod 
ipehoto Biodo 	 pmeuseenno pequrn 
L1atomaod anasI	 mathd 
clot ptod of preirvaigan of op~leions Standard oround Io rc 
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tdpar=ilCOaid for pool flinh boi. acy cqirovd 
Figure II-5A. Typical Gel Preparation Ground Tests 
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Figure II-5B. Typical Gel Preparation Ground Tests (Cont'd) 
I. 2.5 ISOENZYME SEPARATION PROCESS STEP (WBS 5.0)
 
A major R&D effort of 22 Work Elements is required to examine the phenomenology
 
of this key step in isoenzyme production. Typical requirements for this process step
 
are shown inFigure 11-6 for-both the baseline production process and a typical experi­
ment.
 
After successful operation of the process on an experimental basis, further R&D will 
be required to establish the preparative scale equipment and processes as necessary for 
economical throughput. Fundamental questions on appropriate voltage gradients, con­
vection rates, local heating, gel tube effects, path length, buffer type, etc., must be 
answered at both the experimental and preparative scale levels. Throughput require­
ments (on the order of thousands of milligrams of separated antigens per year) raise 
further questions of tube size, tube insertion and removal, chamber emptying in 
zero-G, etc., which can only be resolved with shuttle tests of preparative scale 
equipment. A series of tests is necessary to examine basic phenomena in the ground 
laboratory environment followed by sounding rocket and shuttle flight tests to achieve 
a prototype capability. 
Figure 11-7, I-8, 11-9 are representative Work Element Descriptions, resource 
requirements and resource costs generated for tests covered in this WBS. Initial 
tests will use conventional single or multiple gel tubes of nominally 0. 5 cm diameter, 
as shown typically in Figure II-10. Scaleup efforts will attempt the use of tubes of 5-8 cm 
diameter, as conceived in Figure I-11, to increase the antigen output per run while 
minimizing handling requirements and chamber complexity. 
We have also looked at a less conventional separation system, Figure 11-12, which, while 
it may require more development, appears to be better suited to high output require­
ments of preparative quantities. 
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Item 
Gel Temperature 
Gel Type 
Buffer Type 
Batch Size 

Tube Length 
Tube Diameter 
No of Tubes 
Voltage Gradient 
Voltage Applied 
Current 
Power Required (process) 
Separation Process 
Biological Materials 
Storage Method 
Isolation Method 
Preliminary Separation Method 
Preliminary Preservation Method 
Process Time 
Buffer Prep Time 
Gel Prep Time 
Separator Prep Time (Tubes, Buffer, Cooling) 
Electrophoretic Run Time 
Gel Removal Time 
Gel Placement in Staining Solution Time 
Gel Stain Time 
Stain Wash Time 
Gel Placement in Preservative Time 
Gel Measure & Photograph Time 
Typical Experiment Data 
50 C 
large pore gel 
discontinuous 
few mg 
7.5 cm 
0.5 cm 
I to 9 
<10 volts/cm 

100-400 volts 

2 ma 

1 watt 

gel electrophoresis (or 

isoelectric focusing) 

creatine kinase, etc. 

freezer 

Elution (on ground) 

Ammonium sulfate precipitation, 

column chromatography, 

& dialysis 

lyophilization 

Production Data 
50C 
large pore gel
 
discbntinuous
 
100 mg
 
20-25 cm
 
5-8 cm
 
1
 
<10 volts/cmn
 
300-1300 volts
 
200-400 ma
 
100-500 watts
 
gel electrophoresis (or
 
isoelectric focusing)
 
oreatine kinaso, etc.
 
freezer
 
Elution (on ground)
 
Ammonium sulfate precipitation,
 
column chromatography,
 
& dialysis
 
lyophilization
 
1 hr on ground
 
1. 5 hr 
0.5 hrs in-space 
10-15 ln's 
0.3 hrs 
0.1 hr 
4-5 hrs on ground 
10 hrs 
0. 1 hr 
1 hr 
Figure 11-6. Isoenzyme Separation Process Baseline Requirements 
TASK DESCRIPTION 
TASK TITLE Demonstration of Capability to Perform Pre. 
Scale Separation
 
WES 	 NO. PREPARED BY DATE 
5.1.1.2.6 S.L. 	 7/11/74
 
1. REOUIRED-OUTPUT 
Report on quality of resolution in scale up of five promising
 
isoenzyme systems to preparative scale electrophoresis. Isolation
 
of separated products for further study.
 
REQUIRED INPUT,
 
Based on 5.1.1.2.5, selection of five isoenzyme systems
 
according to their diagnostic reliability and separation
 
potential.
 
3 DESCRIPTION OF EFFORT$ 
1. 	Tissue/sera collection - as in 5.1.1.2.5, but larger
 
amount required.
 
2. 	Tisshe prep - as in 5.1.1.2.5. 
3. 	Purification - as in 5.1.1.2.5. 
4. 	Electrophoresis - set up of prep unit, electrophoresis
 
as in 5.1.1.2.1.
 
5. 	Report - writing and preparation.
 
4 PERFORMANCE PERIOD For each of the five isoenzyme systems, 1 week 
of prep runs. Timetable - after S..1.1.2.5, third quarter of 1976
 
PFrPORMANCF RESPON51B ILITYt 	 APPROVAL 
Ground Lab 	 I 
NOTE CONTINUE NUMBCRED ITEMS ON SEPARATE SHEET AS REQUIRED 
Figure 11-7A. Typical Work Element Task Description for Ground 
su_, Test of Separation Process 
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4 
TASK RESOURCE REQUIREMENTS
 
TASKTI 	 Demonstration of Capability to Perform Preparative Scale 
Separations
WaS NO. PREPARED BY 	 IDATE 
S.1.1.2.6 
 S.L. 
 7/11/74
 
I. PURCHASED MATERIALS, (INCLUDE ASSUMPTIONS) 
,
Chemical reagents*, stainsw, colorigenic enzyme substrates*'
 
photographic supplies*, misc, lab glassware*
 
*Same as needed for 5.1.1.2.1
 
*Same as needed for 5.1.1.2.5
 
2. PURCHASED SERVICES" (INCLUDE ASSUMPTIONS) 
Pathologist*, clinlcian*, building of preparative separator
 
(if commercially available units are not acceptable)
 
wSame as 	needed for 5.1.1.2.5 but for 1/2 time.
 
3. EQUIPMENTI (INCLUDE ASSUMPTIONS) 
Prep. electrophoresis separator, power supply*, copying camera*,
 
storage refrigerator*, cooling bath (circulating), glass
 
chromatography columns*, centrifuge (clinacal)*, deep freeze*,
 
homogenizer*, microscope , UV spectrophotoineter*, fraction
 
collector*, freeze drying unit*, vacuum pump.
 
*Same as 	needed for 5.1.1.2.5.
 
FACILITIES (INCLUDE ASSUMPTIONS) 
One lab *12' x 12' equipped with electrical, plumbing, furniture
 
and hood.
 
*Same as 	needed for 5.1.1.2.5.
 
APPROVAL 
AS REQUIRED.ITEMS ON SEPARATE SHEETNOTE CONTINUC NUMBERED 
Figure 11-7B. Typical Work Element Task Resource Requirements
 
BUS-3 for Ground Test of Separation Process
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WORK ELEMENT COSTS 
WORK ELEMENT N.WORK ELEMENT TITLE 
NO,5 1.1.2.6 
 Capability to Perform Preparative Scale Separation
 
2 3 5 6
ACT. ACTIVIY 7 8LABORSEDNO. SERVICES EQUIPMENT FACILITIES TOTALCOST MATERIALS COST COST COSTCOST COST
 
1 Tissue/sera collection 640 IS0 ­ 915
 
125800

Planning 

525
 
Prep/Run 800 250 1100 1100 
 7,750
 
1050
 
Post Run/Assay 1600
 
525
 
2 Report 640 
 11 1,031
 
380
 
3 Tissue Prep 95 55 ** 675
 
525
 
4 Purification 320 250 
 ** 780 
2100 
**Equipment Used in 5.1 1.2.S
 
***Assuming no cost
 
TOTALS $10,000 $566 $1375 $1100 $13,041 
Figure II-7C. Typical Work Element Task Cost for Ground Test of Separation Process 
TASK DESCRIPTION
 
TASK 	TIT" KC-135 
(Zero G) Tests of Freezer Unit
 
wB 5.1.1.3.2 IPREPAREDBY PTS 

.APE12.74
 
I REQUIRED OUTPUT 
Design confirmation and report on operation of freezer and
 
cooling system on short duration zero-g conditions.
 
2. REQUIRED INPUTI
 
Results of WBS 5.1.1.2.8.
 
3. 01 SCRIPTION OF EFFORT S(See Test lVB)
 
1. 	Assemble and ground test a freezer unit and cooling system as
 
developed in W1BS 5.1.1.2.3, and package for KC-135 flights.
 
2. 	Conduct KC-135 flight tests (40 to 100 runs, 30 seconds per
 
run) to assess freezer operation and cooling system operation
 
at zero-g for short durations in various positions.
 
3. 	Conduct post-flight ground tests and design analysis of
 
returned equipment to assess equipment design.
 
.1 PrRrORMANCE 	 PERtO
 
After 5.1.1.2.8, 1975/79.
 
APPROVAL
 
PrRFORMANCF RESPONSIBILITVI 

Research Lab/Systems Contractor/NASA
 
NOTE CONTINUE NUMBERED ITEMS ON SEPARATE SHEET AS REQUIRED
 
Figure I-8A. 	Typical Work Element Task Description for 
KC-135 Test of Freezer Uit 
BUS1I
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TASK RESOURCE REQUIREMENTS 
TASK TITLE 
KC-135 (Zero-g) Tests of Freezer Unit
 
WE O. PREPARED ax'DATE 
5.1.1.3.2 PTS 12/74 
I. PURCHASED MATERIALS (INCLUDE ASSUMPTIONS) 
Film and other photographic supplies; raw materials for
 
experiment package structure and mounting interconnection, etc.
 
(Assume freezer and recorder available from other tasks)
 
2. PURCHASED SERVICES- (INCLUDE ASSUMPTIONS) 
Project engineering, apparatus design and fabrication, flight

preparation, flight support and post-flight data analysis.
 
(Assume KC-135 aircraft and NASA support are GFE)
 
3. EQUIPMENT (INCLUDE ASSUMPTIONS) 
None (assume freezer and recorder are available from other tasks)
 
See Figure II-8D
 
FACILITIES (INCLUDE ASSUMPTIONS) 
None 
NOTE C ONTINUC NUMOFRrD ITFMS ON SFPARATI SHF T AS I~rcIE[,r -
Figure HI-BB. Typical Work Element Task Resource Requirements 
'is-3 for KC-135 Test of Freezer Unit 
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WORK ELEMENT COSTS
 
WORK ELEMENT NO. 
5.1.1.3.2 
WORK ELEMENT TITLE 
KC-135 (Zero-G) Tests of Freezer Unit 
1 25 PURCHASED 678 7 8 
ACT. ACTIVITY LABOR PURAS SERVICES EQUIPMENT FACILITIES TOTAL 
MATCRCS COST COST COST COST 
1 	 Preflight ground test 1280 3500 5000 - 9780 
2 Flight Test - Contractor - - 2500 - 2500 
NASA Support - 15,000* - 14,000* 
3 	 Postflight Ground Test 
& Analysis 1280 4000 - 5280 
*KC-135 Aircraft and NASA support
 
TOTALS $2560 $3500 $26,500 - $32,560 
Figure f-8C. Typical Work Element Task Cost for KC-135 Test of Freezer Uit 
PAYLOAD EQUIPMENT DEFINITION DATA - SHEET I 
EQUIPMENT NAME 
Freezer (Storage & Preservation) (B 24 E) 
DATE 
12/31/75 
1.AVAILABILITY STATUS* 
K]NEW,REQUIRES YEARS TO DEVELOP So-Low Environmental Equipment Co.,Inc. 
U MODIFICATION OF AVAILABLE EQUIP; COMPANY 
PRESENTLY AVAILABLE; COMPANY 
[-SPACE QUALIFIED, PROGRAM 
F-OTHER
 
2 	EXPERIMENTS ACCOMMODATED (EXPERIMENT NAME OR TYPE) 
e 	Biological Applications
 
3 	DESCRIPTION OF EQUIPMENT OPERATION (MAJOR FUNCTIONS) 
0 	 The unit will be utilized for cold storage or biological samples, 
before and after processing.
Functions: a) Separate sections within the storage compartment with
 
programmable temperature control
 
b) Hold containers within each section to provide positive

containment and to prevent shock damage during launch/
 
landing.

c) Have sufficient insulation, thermal inertia, secondary

cooling capacity in case of primary power malfunction.
 
4. EQUIPMENT PHYSICAL DESCRIPTION (SKETCH, DIMENSIONS, VOLUME) 
* No. Req'd - 1
 
.54m x .84m x .30m = .136m 3
 
* 	wt - 80 kg.
 
5 EQUIPMENT PERFORMANCE PARAMETERS (E.G,FLOW RATE, ENERGY OUTPUT, MAX TEMP, ETC) 
" Temp. Range - -180C to -1840C (Accuracy ±10 C)
 
" Thermal Capacity - 375 btu/hr at -160 0 c
 
Figure 11-8D. Freezer Data (Page 1 of 3)
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PAYLOAD EQUIPMENT DEFINITION DATA - SHEET 2
 
EQUIPMENT NAME DATE 
Freezer (Storage & Preservation) (B 24 E) 
6.INSTRUMENTATION: (E.G., THERMOCOUPLES,,GAUGES,ETC, LOCAL & REMOTE)
 
* Temperature Sensing Device
 
a) Maximum temperature fluid expansion thermometers.
 
b) Chemically treated maximum temperature indicating paper discs.
 
7.SUPPORT SERVICES REQUIRED (E.G , POWER, GASSES, VACUUM, COOLANT, OPERATOR ATTENTION) 
* Power is from 11SV-60Hz main power supply
 
500w peak
 
100w sustained
 
8. EXTERNAL ENVIRONMENT REQUIRED (E.G ,ATMOSPHERE, VIBRATION LEVEL, ETC) 
* Forced cooling of motors and compressors will be necessary.
 
9 EXTERNAL ENVIRONMENT PRODUCED: (E.G., EMI, HEAT,CONTAMINATION, ETC)
 
* EMI generation during compressor start up.
 
10 SAFETY CONSIDERATIONS (EQUIPMENT, OPERATORS, ETC) 
* Guarded against spillage of the fluids.
 
* Glass covers are replaced by polycarbonate plastic.
 
* Refrigerant may be inflammable at the surrounding environment.
 
11. WASTES & PRODUCTS PRODUCED
 
* None
 
Figure H-8D. Freezer Data (Page 2 of 3) 
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.' PAYLOAD EQUIPMENT DEFINITION DATA - SHEET 3
 
EQUIPMENT NAME DATE
 
Freezer (Storage & Preservation) (B 24 E) 

12. 	 DATA INPUT/OUTPUT REQUIREMENTS (AS EXTRACTED FROM ITEM 13) 
Input Control Functions - Programmable temperature selection & regulation.
 
Output Temperature Monitoring
 
13 	 FUNCTIONAL FLOW DIAGRAM (INCLUDE & NOTE AUTOMATED FUNCTIONS, DATA FLOW, CONTROL RANGES 
& LIMITS, ETC) 
PROGRAMMABLE TEMPERATURE
 
SELECTION & REGULATION
 
Elec.
 
Power FREEZER (STO. & PRESV.)
 
In 	 7 
DESIRED TEMPERATURE
 
Figure H-8D. Freezer Data (Page 3 of 8) 
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TASK DESCRIPTION
 
TASK TITLE 
Shuttle Tests (Zero-G) of Separation System
 
WBS NO. TPREPARED BY 	 DATE 
5.4.1.4.1 PTS 	 12/74
 
I REQUIRED OUTPUTI 
Design configuration and report on operation of electrophoresis
 
system (separator, freezer, cooling system, power unit) in
 
zero-G for long durations. Recommendations for design modification
 
to improve operation in zero-G.
 
2 REQUIRED INPUT: 
Results of WBS 5.1.1.3.1, 5.1.1.3.2, 5.1.1.3.3. 
3, DESCRIPTION OF EFFORTI (See Test IV A) 
1. 	Assemble and ground test an electrophoresis separator system
 
(separator, buffer storage and transfer, specimen loading,
 
cooling system, automation & controls) as developed in WBS
 
5.1.1.3.1, 5.1.1.3.2 and 5.1.1.3.3, and package for shuttle
 
experimental flights.
 
2. 	Conduct shuttle test flights (1 to 2 flights, 1 or 2 runs of
 
1 day each) to assess system operation in long duration zero-g
 
conditions. Gather photographic and other data.
 
3. 	Conduct ground lab tests of returned equipment and get to
 
assess equipment design and electrophoretic separation
 
results.
 
PERFORMANCE PERIOD
 
After 5.1.1.3, 1979-1982
 
PFRFORMANCE RESPONSIB ILITYt 	 APPROVAL 
Research Lab/Systems Contractor/NASA
 
NOTE CONTINUE NUMBERED ITEMS ON SEPARATE SHEET AS REQUIRED 
Figure ll-9A. Typical Work Element Task Description for 
BUS-, Shuttle Test of Separator System 
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4 
TASK RESOURCE REQUIREMENTS 
TASK TITLE 
Shuttle Tests (Zero-G) of Separator System
 
WBS NO. PREPARED BY DATE 
5.1.1.4.1 PTS 
 12/74
 
I. PURCHASED MATERIALS (INCLUDE ASSUMPTIONS) 
Raw materials for construction and modification of apparatus;
 
photographic and biochemical supplies.
 
2. PURCHASED SERVICES (INCLUDE ASSUMPTIONS)
 
Systems contractor apparatus fabrication and test, flight

support, and post flight data analysis (Assume Shuttle service
 
and NASA support as GFE)
 
3 EQUIPMENT (INCLUDE ASSUMPTIONS) 
onitoring equipment and experiment apparatus (pump, valves,
 
controls)
 
4. rACILITIFS- (INCLUDE ASSUMPTIONS) 
None
 
APPROVAL 
NOTE: CONTINUE NUMBERED ITEMS ON SEPARATE SHEET AS REQUIRED. 
Figure 1-9B. Typical Work Element Resource Requirements 
BUS-3 for Shuttle Test of Separator System 
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WORK ELEMENT COSTS
 
WORK ELEMENT NO, WORK ELEMENT TITLE5.1.1.4.1 Shuttle Tests (Zero-G) of Separator System
 
2, 3 4' 5 6 7 8 
ACT. ACTIVITY LABOR PURCHASED SERVICES EQUIPMENT FACILITIES TOTALNO. COST MATERIALS C SNO. COST COST COST COST COST COST
 
1 Equipment preparation and 
 26000 80000 95000 72000 -- 201,000 
test (2 flights) 
2 Flight Test (2 flights) - ­ 18000 - 18,000 
NASA Space Charges 
- 264000 
-- 264,000 
3 Post-flight test (2 flights) 2400 2000 8000 
 34,000
 
TOTALS $50,000 $10,000 $385,000 $72,000 -- 517,000 
Figure I-9C. Typical Work Element Task Costs for Shuttle Test of Separator System 
4PAUL VALLEY INDUSTRIAL PARK WARRINGTONPENNA18976 PHONE215-
EQUIPMENT AND CHEMICALS FOR POLYAC1ILYAMIDE GEL ELECTROPHORESIS 
HOEFE R electrophoresis unit-polyacrylamide gel
 
Versatile 
Up to 12 gel tubes fit in the tipper buffer chamber 
The standard lower buffer chamber accommodates gel tubes 
from 2 ' to 5 ' long an optional lower chamber allows tubes 
up to 8" long 
The standard single walled chamber is well suited for work at 
ambient temperatures for temperature control work adouble walled thermolaeketed chamber is available 
Separation and destaining can be accomplished in the same 
unit 
Convenient 
The whole unit is compact enough to fit easily into a 
refrigerator 
Rubber stoppers are fitted on the gel tubes before the glasstubes are placed in the tapered holes of the upper chamber 
An affixed level and levelling screws insure perfect vertical 
alignment A tube aligning plate simplifies the alignment pro 
(edure and is easily visible because transparent plastic isused 
throughout the unit 
Safe 
Great strength is ai~ee by using 1/ thick ac rylic plastri, in 
both the upper and lower buffer chambers 
The sealed central power core is the only source of (urrent 
giving positive protection against accidental contacL with 
buffer 
Elerodes running in protected grooves around the outside 
surface of the power Lore are at all times out of reach of the 
operator shands 
A satety lid makes 'ertain that the unit cannot be opened
wdthspcapugadvlaeables are attached 
Figure 11-10. Typical Available GEL Electrophoresis Units 
tEPRODUCiBILITY OF THU 
ORIGINAL PAGE 18 RUM 
H-28 
CONCEPT:
 
GEL TUBE. 5TO 8 CM DIAM, 20 TO 25 CM LENGTH 
CHAMBER 15 TO 30CM DIAM, 28 TO 30 CM LENGTH 
POWER SUPPLY: 300 TO 1500V 
EMPTYING METHOD TBO (ACCUMULATION, ELECTRODES 
PISTON, ETC) C-
()
LIPOWPER UPLY 
LOWERCONTROLS (CURRENT RED) 
UPPER PROTEIN CHARGE 
BUFFER 
RESERVOIR(S) 1 UPP BUFFER CHAMBER 
PUMPU 
CONTROLS UPPER i i 
1O1IL11T UPPER BUFFER 
OUTLETNLET 
GEL TUBE 
COOLANT nil GEL
 
RESERVOIRS
 
PUMP,
 
COOLER & 
 COOLANT
 
CONTROLS OUTLETBUFFER.
 
INLET
 
LOWERINE
 
BUFFER
 
LOWER
RESERVOIR(S)

PUMP BUFFER LOWER BUFFER CHAMBER 
CONTROLS OUTLET 
END CAP OR PLUG
 
TUBE 
 GELTUBE
FREEZER 
(TUBE 
STORAGE) END CAP
; t" '-ORPLUG 
MULTIPLE COLUMN 
0OPTIO N 
Figure HI-i1. Large Pore Gel Electrophoresis Facility Concept 
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870 
COOLING PLATE CLAMPS 
17_________ __________,____UICK 	 FITiINGS FORO0 	 CONNECT 
17 00BUFFER 	 FLOW& DRAWING 
X1600, 
RKTSMOUNTING 
COOLING PLATE HINGES 
TRANSPARENT COOLING PLATEI 
THERMAL GREASE BETWEEN CHMBER BASE 
SPECMECOOLING PLATES &SPECIMEN 
CLAMP 
GEL 	 300 
BUFFER COOLING PLATE
 
GEL PAD ELECTRICAL CONNECTIONS
 
ITEM 	 WEIGHT (KG) VOLUME (M3) 
SEPARATOR (SINGLE TUBE) 3.6 01 
BUFFER 5.5 
POWER SUPPLY 9.2 .03 
FREEZER 81 8 .14 
COOLING SYSTEM 13.6 .06 
COOLANT 	 13.6 -

CONTROLS 45 .02 
STRUCTURE &MISC 48.2 24 
TOTAL 	 180 KG 50 M3 
Figure H-12. 	 Large Pore Gel Electrophoresis Facility Concept-
Rectangular Duct Approach 
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A third approach has been documented by TRW(2 ) , as a Beckman version. Its capabilities 
are given in Figure H-13. 
Other equipment potentially capable of being utilized in this process step are docu­
mented in Figures 11-14, 11-15, and 11-16. 
While further scaleup of small tube systems can be accomplished by increasing the 
number of separation chambers on a flight, once an acceptable configuration has been 
demonstrated, our conclusion is that the rectangular duct separator will likely be the 
best business solution. It is shown in Figure 11-17, as it would be mounted for testing 
in a rack of the Spacelab. For commercial operations, we feel that the items listed 
in Figure 11-18 represent the state of equipment, and the quantities needed for this 
program. 
Past space processing study experience (3) has indicated the need for early identification 
and definition of special requirements related to space processes. Figure 11-19 lists 
special requirements reviewed for Space Processing of Isoenzymes. 
11. 2.6 ISOENZYME/ANTIBODY PREPARATION PROCESS STEP (WBS 6.0) 
An R&D effort for this process step is required in order to establish the experimental 
and preparative techniques for physical removal of antigens from gel tubes as received 
from the in-space process step (WBS 5.0). Techniques must also be developed for 
subsequent processing to achieve a final product (gamma globulin fraction) and pro­
duction of commercial quantities. This process step will require: 
- gel removal from tube, slicing and antigen slice selection 
- antigen grind, buffer, and freeze dry 
- preparation of animal injections 
(2)Requirements and Concepts for Materials Science and Manufacturing in Space 
(3 Payload Equipment Study, NAS 8-28938, July, 1973. 
3	 Vouch, G and Bloom, H, Free Suspension Process-A Review of Selected User
 
Interests and Requirements, AIAA Paper No. 74-649, AIAA/ASME 1974 Thermo­
physics and Heat Transfer Conference, July 15-17, 1974.
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PAYLOAD EQUIPMENT DEFINITION DATA - SHEET 1
 
EQUIPMENT NAME DATE 
Stationary Electrophoritic Column (B 12 E) 1/2/7.S
 
1. AVAILABILITY STATUS, 
W] NEW, REQUIRES YEARS TO DEVELOP (Beckman Instruments)
 
rl MODIFICATION OF AVAILABLE EQUIP; COMPANY
 
H PRESENTLY AVAILABLE; COMPANY
 
H SPACE QUALIFIED; PROGRAM
 
[ OTHER
 
2. EXPERIMENTS ACCOMMODATED. (EXPERIMENT NAME OR TYPE) 
* Biological Applications
 
3. DESCRIPTION OF EQUIPMENT OPERATION (MAJOR FUNCTIONS) 
* The buffer solution is placed in the column.
 
* The operating voltage gradient and processing temp. are established.
 
" The sample to be separated is injected into the column.
 
* The separation process is monitored.
 
* The desired fractions are collected at the end of the process.
 
4 EQUIPMENT PHYSICAL DESCRIPTION (SKETCH, DIMENSIONS, VOLUME) 
* No. req'do - S 
* .27m x .03m x .03m = .000243m3
 
* wt - 1.36kg
 
5 EQUIPMENT PERFORMANCE PARAMETERS (E.G, FLOW RATE, ENERGY OUTPUT, MAX TEMP., ETC) 
* Operating temp. range -100C to +50C with accuracy +10 C. 
* Separation velocity accurate up to + I mm/sec 
3
* The total b uffer and sample volumes to be handled -25 cm . 
* Estimated power requirement 100-200 watts.
 
" Voltage gradient - I to 100 v/cm and current density 1-100 mA/cm 2
 
Figure I-13. TRW-Identified SeparationSystem (Page I of 3) 
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PAYLOAD EQUIPMENT DEFINITION DATA - SHEET 2
 
EQUIPMENT NAME DATE 
Stationary Electrophoretic Column (B 12 E) 
6. INSTRUMENTATION: (E.G., THERMOCOUPLES, GAUGES, ETC, LOCAL & REMOTE) 
o Not defined
 
7. SUPPORT SERVICES REQUIRED. (E.G., POWER, GASSES, VACUUM, COOLANT, OPERATOR ATTENTION) 
o Power from power conditioner (5 kv).
 
o A regulated, controllable dc voltage supply.

* An optical monitoring system with capability of position
 
indexing system.
 
o Active cooling control.
 
* An electrode gas elimination systme with connections to the columns. 
8 EXTERNAL ENVIRONMENT REQUIRED: (E.G., ATMOSPHERE, VIBRATION LEVEL, ETC) 
a None
 
9. EXTERNAL ENVIRONMENT PRODUCED- (E.G., EMI, HEAT, CONTAMIINJATION, ETC) 
@ None
 
10. SAFETY CONSIDERATIONS: (EQUIPMENT, OPERATORS, ETC) 
@ Electrical interlocks against electrical shocks.
 
e Radiation shielding for possible eye damage by radiation from
 
the monitoring system.
 
11. WASTES &PRODUCTS PRODUCED 
* None
 
Figure 11-13. TRW-Identified Sepaiation System (Page 2 of 3) 
11-33 
PAYLOAD EQUIPMENT -DEFINITION-DAT-A --SHEET 3 
,EQUIPMENT NAME DATE 
Stationary Blectrophoretic Columns 
(B 12 B) 	 1/2/75 
12. 	 DATA INPUT/OUTPUT REQUIREMENTS (AS EXTRACTED FROM ITEM 13) 
" Input Control Functions - Maintenance of voltage gradient, column
 
temperature, and monitoring of sample fraction separa-tion veloci-ties.
 
* Data Output - Temperaure, power input, and separation velocity.
 
13. 	 FUNCTIONAL FLOW DIAGRAM (INCLUDE & NOTE AUTOMATED FUNCTIONS, DATA FLOW, CONTROL RANGES
 
&LIMITS, ETC)
 
* Not defined
 
Figure 11-13. TRW-Identified Separation System (Page 3 of 3) 
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PAYLOAD EQUIPMENT DEFINITION DATA - SHEET 1
 
EQUIPMENT NAME 
PH Monitor (B 15 E) DATE 12/31/74
 
1. AVAILABILITY STATUS. ­
[] NEW, REQUIRES YEARS TO DEVELOP 
F- MODIFICATION OF AVAILABLE EQUIP; COMPANY 
[] PRESENTLY AVAILABLE, COMPANY Beckman Instruments, Inc.
 
F- SPACE QUALIFIED, PROGRAM
 
[] OTHER
 
2 EXPERIMENTS ACCOMMODATED' (EXPERIMENT NAME OR TYPE) 
* Biological Applications
 
" Chemical Processes in fluids
 
3 DESCRIPTION OF EQUIPMENT OPERATION (MAJOR FUNCTIONS)
 
" PH monitor is used to measure the acidity or alkalinity of solutions.
 
4 EQUIPMENT PHYSICAL DESCRIPTION (SKETCH, DIMENSIONS, VOLUME) 
" No. req'd. - 1
 
e .37m x .46m x .30m = .051m 3
 
* wt - 10kg
 
* Metal enclosed, rack or panel mounted
 
5 EQUIPMENT PERFORMANCE PARAMETERS (E.G, FLOW RATE, ENERGY OUTPUT, MAX TEMP, ETC)
 
* Data Output - 1 bit per second . Liquid Temp. Range -0°C to 1000C 
o Range - 0-12 pH units 
* Spans - 2, 5, or 10 pH units 
* Ambient Temp. Coeff. +.002 pH/ 
oC 
" Stability - -+0°02pH units 
* Ambient Temp. Range - -70C to 500C 
Figure 11-14. Typical Instrument (Page I of 3)
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PAYLOAD EQUIPMENT DEFINITION DATA - SHEET 2
 
DATEEQUIPMENT NAME 
PH Monitor (B 15 E) 12.31/74
 
6. INSTRUMENTATION: (E.G., THERMOCOUPLES, GAUGES, ETC, LOCAL & REMOTE) 
* Amplifier and Indicator Units.
 
* Reinforcement of the control panel against acceleration and shock.
 
* Thermo compensator.
 
e Lazaran (TM) or equivalent reference electrode is used for low-g
 
operation.
 
7. SUPPORT SERVICES REQUIRED: (E.G., POWER, GASSES, VACUUM, COOLANT, OPERATOR ATTENTION) 
* Peak (sustained) power - 20 watts.
 
* Manual Temperature Condensation (if automatic control not developed)
 
8 EXTERNAL ENVIRONMENT REQUIRED. (E.G., ATMOSPHERE, VIBRATION LEVEL, ETC) 
e None
 
9. EXTERNAL ENVIRONMENT PRODUCED. (E.G., EMI, HEAT, CONTAMINATION, ETC) 
e None
 
10. SAFETY CONSIDERATIONS: (EQUIPMENT, OPERATORS, ETC) 
* Meter covers are made of polycarbonate plastic instead of glass.
 
* No toxic or potentially flammable materials are known to be present.
 
11. WASTES & PRODUCTS PRODUCED 
* None
 
Figure I-14. Typical Instrnment (Page 2 of 3) 
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PAYLOAD EQUIPMENT DEFINITION DATA - SHEET 3
 
EQUIPMENT NAME DATE 
PH Monitor (B 15 E) 12/31/74
 
12. 	 DATA INPUT/OUTPUT REQUIREMENTS (AS EXTRACTED FROM ITEM 13) 
" Input - Either 28v dc or ll0v ac, 400 	hz
 
e Output in form of a voltage shift (0-10 or 100 mV or 0-1 or 5v dc)

displayed on a meter.
 
13. 	 FUNCTIONAL FLOW DIAGRAM (INCLUDE & NOTE AUTOMATED FUNCTIONS, DATA FLOW, CONTROL RANGES 
& LIMITS, ETC) 
Elec. PwrIn Pr Monitor 	 Voltage shift displayed on a
 
meter depending on the hydrogen
 
ion concentration.
 
Figure 1--14. Typical Instrument (Page 3 of 3) 
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PAYLOAD EQUIPMENT DEFINITION DATA - SHEET 1
 
EQUIPMENT NAME DATE
 
Fluid Cooling/Refrigeration Unit (B 1 E) 
 1/2/75
 
1 AVAILABILITY STATUS-
WX NEW, REQUIRES YEARS TO DEVELOP So-Low Environmental Equipment,Co.,Inc 
U MODIFICATION OF AVAILABLE EQUIP; COMPANY 
LI PRESENTLY AVAILABLE; COMPANY 
LI SPACE QUALIFIED, PROGRAM 
B OTHER 
2 EXPERIMENTS ACCOMMODATED: (EXPERIMENT NAME OR TYPE) 
* Biological
 
3 DESCRIPTION OF EQUIPMENT OPERATION (MAJOR FUNCTIONS) 
* Must monitor the temperature and provide positive temperature

control to the buffer and sample solutions, the stationary and
 
continuous flow electrophoretic columns, the gas elimination
 
systems, and the collected fractions from the continuous flow
 
electrophoretic column.
 
4 EQUIPMENT PHYSICAL DESCRIPTION (SKETCH, DIMENSIONS, VOLUME) 
* No0 Req'd. - 1
 
* 1.34m x .82m x .94m = 1.033m 3
 
" wt - 180kg 
5 EQUIPMENT PERFORMANCE PARAMETERS (EG, FLOW RATE, ENERGY OUTPUT, MAX TEMP, ETC) 
o Data Output - 28 bits per second
 
* Temp. Range (-250C to +45oC) with accuracy ±o0c
 
o Max. Heat Load to be rejected during a process run-2000 watts.
 
Figure 11-15. Typical Refrigeration Unit (Page I of 3) 
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PAYLOAD EQUIPMENT DEFINITION DATA - SHEET 2 
EQUIPMENT NAME 
Fluid Cooling/Refrigeration Unit (B 1 E) 
DATE 
1/2/75 
6. INSTRUMENTATION: (E.G., THERMOCOUPLES, GAUGES, ETC, LOCAL & REMOTE) 
a Temperature Sensing Device 
7. SUPPORT SERVICES REQUIRED: (E6, POWER, GASSES, VACUUM, COOLANT, OPERATOR ATTENTION) 
Power from 1lSV 60Hz supply: Peak -1592w
 
Sustained -746w
 
" The gas elimination system must be warmed to near ambient temperature
 
in order to separate and remove the dissolved gases from buffer. 
" Cooling and heating jackets a Forced air cooling of compressor unit 
" Power input cables 
" Temperature sensors
 
8 EXTERNAL ENVIRONMENT REQUIRED (EG, ATMOSPHERE, VIBRATION LEVEL, ETC) 
* None
 
9 EXTERNAL ENVIRONMENT PRODUCED. (EG, EMI, HEAT, CONTAMINATION, ETC) 
* EMI Generation during compressor start up.
 
10. SAFETY CONSIDERATIONS (EQUIPMENT, OPERATORS. ETC) 
a Guarded against fluid spillage 
* Any glass cover can be replaced by polycarbonate plastic 
a The refrigerant should not be inflammable at operating environment 
11. WASTES & PRODUCTS PRODUCED 
o None
 
Figure 11-15. Typical Refrigeration Unit (Page 2 of 3) 
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PAYLOAD EQUIPMENT DEFINITION DATA --SHEET 3
 
EDIUIPMENT NAME 	 DATE 
Fluid aodling/Refrigeration Unit 
(B I E) 
 1 2 75
 
12. 	 DATA INPUT/DPrPUT REQUIREMENTS AS EXTRACTED FROM ITEM 13) 
* The input control functions - Temperature monitoring and provide
 
sufficient'flow rate of the coolant fluid to maintain the desired
 
temperature.
 
o Data output - Temperatures, and flow rate
 
FUNCTIONS, DATA FLOW, CONTROL RANGES13 	 FUNCTIONAL FLOW DIAGRAM (INCLUDE & NOTE AUTOMATED 
& LIMITS, ETC) 
Programmable Temperature
 
Selection & Regulation 
Regulatio 
Control to Ihe 
Electric Flu ni 1Flow Rate of the 
Desired Temperature
 
and Flow Rate
 
Figure 1-15. Typical Refrgeration Unit (Page 3 of 3) 
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HOEFER D.C. power supply
SCIENTIFIC 
INSTRUMENTS MicroAnalytical Instruments For Biochemical Research 
S.. Fr aencisc loHoe tr ,S,ieftific 
.10 
3e 
 A COMPACT, SOLID STATE POWER SUPPLY
 DESIGNED FOR GEL ELECTROPHORESIS 
All lii jhld elate .t..posentsisule dependable power in Scale selection switches enable the operator to read low cur 
the l, Ar the ild room. rents and voltages with full scale accuracy. This is especially 
Ciri nit design offers full prote ltion against short circuit dam- useful in operations which use less than one milliarp of cur 
per tube.Arent 
Taut band meeles are durable and ir be read easily Specifiostom 
Handlt ar, tIh, nuke the unit Constant voltage 0 to 400 VDCiorporated .t..he design to 
emily portable They also provide tspm ial protection for theGut ~Iii Constant 0 to 80 mapane curren't 
Load regulation +o 15%
 
Function Line regulation +0+2%
 
The sirrent and voltage have pepiirte c introlt and separate Ripple reiection 74db
 
lilnoers This dral arringement lirniite ,wkward switching 
bai k aid forh imposed by sigle metef inodels A ten turn 
pole lii.... r..ci .ureul easy and ji.,uate Ordriu Irnformatonre . id finting the 
Two pairs of ottput ternmilscs enable the operator 1o use two PS 01 DC Power Supply 0400 VOC, 0-80 ma. onstant 
deorophoresis cells simulineously Each pair of output term ret coer oltagn 
nealshas a polarity reversing switsh. There is no red to re current, constant voltage 
verse the leads Shipping Weight 20 lbs. Price: $360.00 
HOEFER SCIENTIFIC INSTRUMENTS - 520 Bryant Street, San Francisco, California 94107 - (415) 398-1642 
Figure H-16. Typical Power Supply 
OF Tag ll-41 uu ir 
gniUhL flGa 5C 
,EXPERIMENTELECTROPHOESISLAB J 
COOLING PLATE LATCH -COOLING PLATES 17.75 
CONNECT FITTINGS 
A 
LIGHT"
 
H'T .. 14.00-

RACK MOUNTING 
52.50 
\ELECTRICAL 
17.50CONNECTORS 

-BUFFERINPUT& 
OUTPUT PORTSM NTING A 
.
CLAMP B 

TRANSPARENT 

DOORA COOLANT FLEX LINES "
 
PRISM '-CAMERA '
 
CHAMBER MTG PLATE 
9.900, " 
STANDARD 
RACK MONT' 
Figure 11-17. Shuttle/Space Lab Gel Electrophoresis Experiment 
- m mim Il•Hm mm H I l n ai a - Ia| mmI 
Item 
Space 
Development 
Required? 
Quantity 
Required 
Initial 
(Ground Test) 
Quantity 
Required 
Prototype 
Quantity 
Required 
Pilot 
Quantity 
Required 
Production 
Analytical 12 Col Electrophoresis Yes 1 - - -
Separator 
Preparative I-Col. Separator Yes 1 1 1 2 
Power Supply, Electrophoresis Yes 1 1 1 2 
Cooling Bath (Circulating) & Pump Yes 1 1 1 2 
Copying Camera No 1 1 1 -
Storage Refrigerator Yes 1 1 1 
Deep Freeze Yes 1 1 1 
Freeze Diying Unit Yes 1 1 1 -
Vacuum Pump No 1 1 1 1 
Circulating Hot Water Bath Yes 1 1 1 1 
Thermocouples & Meters No 1 set 1 1 1 
Gas Chromatograph No 1 1 - -
Centrifuge (Clinical) No 1 - - -
Homogenizer No 1 - - -
Microscope No 1 - - -
UV Spectrophotometer No 1 - - -
Fraction Collector Yes I 1 1 1 
Figure I-18. Development Equipment List 
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Requirement 	 Equipment or Operational Need 
Safety 
* Temperature 	 No crew-or missibn hazard 
* Toxic or Corrosive Mat'l Buffer fluids are corrosive. 
Positive seals, purging required 
for repetitive batch operations. 
• 	 High Voltage Up to 1300 volts possible. Stand­
ard electrical safety fusing and 
grounding required. 
Waste Control 
* Gas, Liquid, Solid 	 All gel electrophoresis products 
are contained in gel tube. (If 
decision to form gel in orbit is 
made, evolving gases must be 
collected.) 
* Heat 	 Ohmic heating must be extracted. 
Sterility 	 Critical requirements. All pro­
cess equipment must be pre­
packaged sterile. Fresh equip­
ment for each new material, or 
lab grade sterilization procedure 
and equipment must be provided. 
Figure 11-19. Special Requirements for Space Processing of Isoenzymes 
- antiserum preparation in animals 
- extraction of antiserums and preparation of gamma globulin fractions 
- preparation of kits for use by clinicians (final product) 
The functions involved are conventional and therefore the development effort will be 
concerned with establishment of specific 	equipment and techniques and accommodation 
of throughput requirements. For example, animals used for antiserum preparation 
might be rabbits or goats, but throughput 	considerations suggest the use of larger 
animals such as horses. A throughput on the order of one million kits per year would 
H-44 
require maintenance of perhaps 100 horses or more, depending on the number of 
different antigens processed. The testing of experimental kits with humans, which 
would be necessary before commitment to preparative scale operations, must also 
be addressed. This testing, as well as the final product, would be based on a diagnostic 
kit (one per patient) with a separate kit required for each disease to be diagnosed, such 
as a particular type of cancer. The ultimate objective for a given kit would be to 
achieve 90-95% effectiveness in diagnosis that a disease is present, and an equivalent 
effectiveness in diagnosing that a disease is not present. Arrangement of tests for 
diagnostic kits will be established with hospitals or clinics during the ground lab test 
phase, to obtain preliminary, relatively crude indications of antigen effectiveness. 
These indications will then form the basis for zero-G tests of particular isoenzymes 
separations, and further antigen tests. 
A series of laboratory tests and clinicsl trials will be performed to determine first 
indications of antibody efficacy based on best ground-based methods. About 10 anti­
body/antigen systems will be examined. These findings will form the basis for in­
space processing of the most promising isoenzymes. The laboratory tests will 
consist of complement fixation testing to determine the amount of antibody obtained, 
and immuno-diffusion testing to determine the purity of the antibody samples. The 
clinical trials will be conducted with volunteer patients and collaborating physicians. 
The patients will be high-risk candidates where perhaps 10% of the patients actually 
have the disease being diagnosed. After patient diagnosis, a follow-up study of each 
patient (about one year) will be conducted to determine whether the diagnosis gave false 
positive or false negative indications. 
Following the ground-based tests, a similar series of tests will be conducted to com­
pare the space-processed product with the earlier ground-processed product results. 
The findings of this comparison will form the basis for on-going space processing. 
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When pilot plant and full-scale production activities are instituted, routine evaluation 
of space-processed products will be necessary as a quality control measure, The 
method for this evaluation will be essentially the same as described above for the 
development program. 
H. 3 DEVELOPMENT SCHEDULE 
The development schedule, Figure 11-20 indicates the emphasis to be placed on in­
vestigation of the phenomenological questions which must be answered for the large 
pore gel electrophoresis separation process. These activities (WBS 5. 0) will address 
the enzyme mobility, convection, path length and other topics initially in a ground 
laboratory environment in the period 1975-1977. Apparatus requirements are ex­
pected to evolve as the phenomena become understood, so that. the equipment designed 
for zero-G operation in sounding rocket tests and later shuttle tests should need 
relatively few design modifications as the result of flight tests. The number of flights 
shown presumes successful anticipation of zero-G requirements during the ground 
laboratory test phases. 
The point at which a business decision can be made to proceed into the pilot/production 
phase is undetermined, but presumably would occur about 1981, when the first results 
of shuttle-based experiments are known and the first isoenzyme samples have been 
tested. This timing would allow an orderly preparation for full scale production which 
would be achieved about 1985. The financial forecast assumed small scale production 
and initial sales in 1982, which presumes that a small pilot capacity is established in 
that year, with at least one successful isoenzyme isolation having acceptable product 
efficiency. 
The time available between 1975 and the shuttle availability allows an adequate period 
for accomplishment of the required research and development work. However, the 
crucial nature of the information to be gotten from the phenomenological investigations 
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TAS K WBS 7 76 J77 1 78 79 80 81 82 83 84 85 
DEVELOPMENT LAB TEST SR TEST PROTOTYPE TEST 
PROGRAM MANAGEMENT 1.0 PLAN_1_R1 PRODUCTION RE'TS 
SR REWTS SH HEQ'TS POUTO ETSYSTEM ENGINEERING 2.0 A I A I 
BUSINESS PATENT NASA SERVICE I 
BUSINESS OPERATIONS 30 A PLAN RIGHTS A ARRANGEMENT A 
A PRODUCTION FULL-SCALE 
GEL PREPARATION PROCESS 40 ORGANIZATION PRODUCTION 
GROUND LAB TESTS 41 12
 
LAUNCH ENVIRON TESTS 4.2.121
 
STORAGE TESTS 4.1.1 22 ANALYTICAL SCALE
 
EQUIPMENT DEVELOPMENT 4.1.2 SEPARATOR L I - SCPARALE
 I SEPRTOR 
ISOENZYME SEPAR PROCESS 50 
GROUND LAB TESTS 5.1.1.2 
ENZYME MOBI LITY TESTS 5.1.1.21
 
CONVECTION TESTS 5.1122
 
PATH LENGTH TESTS 51.1.23 SR = SOUNDING ROCKET
 
RESOLUTION TESTS 51.1.2.4 SH = SHUTTLE
 
SEPARATION TESTS 51125 I
 
PREP SCALE TESTS 51 126
 
ENVIRON TESTS 5.1127
 
SEPARATOR DES FOR 0-G 5.11.2.8
 
SOUNDING ROCKET TESTS 5113
 
(OR RC-135) S1 SR2 
ASEPARATOR TESTS 5.1.13.1 

FREEZER TESTS (KC-135) 5.1.1.32
 
KC-135
 
SHUTTLE TESTS 5114 SI SH-2
 
SEPA RATO R TESTS 51141A 
 A
 
PROTO/PROOF TESTS 5.1 14.2 SH3A SH4Al
 
EQUIPMENT DEV &TEST 5.1.2 LAB A SR EQUIP A SH ,PROTO
 
ISOENZYME/ANTIBODY PREP PROCESS 60 El JIP EQUIP EQUIP
 
STORAGE & HANDLING 61121 i HORSEA
 
EFFICACY OF ANTIBODIES 6.1122 _ I I_ _ FARM
 
Figure 11-20. Isoenzyme Processing Development 
suggests that this work be accomplished as soon as possible, to confirm the feasibility 
or non-feasibility of the product concept. A key activity for making this determination 
is that for testing the efficacy of antibodies (WBS 6. 1.1.2.2) wherein the sample 
antigens obtained from ground laboratory and in-space separations will be tested in 
clinical situations to obtain first confidence in isoenzyme selection, and to determine 
diagnostic capabilities of the samples. 
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SECTION III 
RESOURCES PLANNING 
As in the preceding section, which extracted the program activities, their key mile­
stones and timing, from the documented Work Elements in order to provide develop­
ment Planning data, we also analyzed the Resource Requirements and Resource Costs 
documents to extract the Resource Planning data. 
Based on these requirements and costs, we have delineated the planned allocation of 
development costs for the Iso enzyme program under study. For programmatic purpose 
these allocations have been assembled under several combinations of categories: type 
of resource, WBS elements, timing, and for both Case A and Case B. 
A summary of the estimated costs for Case A, broken down by major resource cate­
gory, is shown in FigureIlI-IA for each major WBS Element and in figure II -1B for 
lower level WBS Elements. The $3. 8 million total program cost includes the cost of 
Sounding Rocket Motors and NASA service charges for Sounding Rocket, KC-135 and 
Shuttle flights in the R&D phase. 
A time-phased statement of those same costs for Case A is given in Figure r1-2, 
broken down to the lower levels of WBS elements. 
Case B costs for R&D (wherein the User does not bear the proof-of-process-feasibility 
costs) are shown in Figure IlI-3. 
It is important to recognize that costs are, in some cases, only measures of resources 
such as personnel with key skills, facilities, special equipment, etc. A tabulation of 
such resources by WBS element is shown in Figure 1M-4. 
rn-1 
WBS Work Element Task 
Labor 
Cost 
Purchased 
Materials 
Cost 
Services 
Cost 
Eqmpment 
Cost 
Facilities 
Cost 
Total 
Cost 
Time 
Period 
1.1 Program Management - 347K 347K 75-83 
2.1 System Engineering - - 316K 316K 75-83 
3.1 Business Operations 
- - 75 onward 
4. 1 Gel Preparation 
Process 
37K 1K 26K 2K 66K 1977 
5.1 
6.1 
Separation Process 
Antibody Prep. Process 
837K 
11K 
469K 
1K 
1552K 
12K 
208K 3066K 
24K 
75-83 
77-83 
TOTALS 885K 471K 2253K 210K' 3819K 
Figure IIH-IA. Isoenzymes Research & Development Program Cost Summary-Case A 
Labor Purchased Services Equipment Facilities Total TimeWBS Work Element Task 	 Cot Matenals 
Cost Cost Cost Cost Cost Cost Period 
1.1 Program Management 47K 	 75-833--	 347K 
2.1 System Engineenng -- 316K 	 316K 75-83 
3.1 Business Operations 
4. 1 Gel Preparation Process 	 37. OK 1.4K 25.6K 2. OK -- 66.OK 1977 
4.1.1 Process Development 	 37.0K 1.4K 25.6K 7.OK -- 66.OK 1977 
4. 1.1.1 Project Supervision 6.0K .. ...... 	 6.OK 1977 
4.1.1.2 Ground Lab Tests 	 31.01K 1.4K 25.6K 2. OK -- 60. OK 1977 
4.1.1.2.1 Launch Environ Tests 	 10.3K 0.7K 25.6K 2.OK -- 38.6K IQ77 
4.1.1.2.2 Storage Tests 	 20.7K 0.7K ...... 21.4K 21177 
4. 1.2 Equipment Development .... ........ 	 1977
 
5. 1 Separation Process 	 837K 468.5K 1551.9K 208.3K -- 3065.7K 75-83 
5. 1.1 Process Development 	 533K 368.5K 1551.9K 158,3K -- 2611.7K 75-83 
5.1. 1.1 Project Supervision 	 237K .. ...... 237K 75-83 
5.1.1.2 Ground Lab Tests 121.4K 25.0K 174.4K 14.3K -- 335.1K 75-78 
5.1.1.2.1 Enzyme Mobility Tests 8.8K 0.5K -- 1.8K -- 1L. IK 1H75 
5.1.1.2. 2 Convection Tests 	 35.6K 0.5K -- 0.6K -- 36.7K 21175 
5.1.1.2.3 Path Length Tests 9.0K 0.8K 0.6K .... 	 10.4K 1Q76 
6.1.1.2.4 Path Length Isoelec. Tests 8.8K 0.6K ...... 	 9.4K 2Q76 
5.1.1.2.5 Best Ground Method Tests 	 39.4K 1.6K 3.8K 6.8K - 51.6K IH76 
5.1.1.2. 6 Preparative Scale Tests 	 10. OK 0.6K 1.4K 1. OK -- 13. OK 3Q76 
5.1.1.2.7 Environmental Tests 3.4K 0.1K 70.OK 4.1K -- 77.6K 2Q77 
5.1.1.2. 8 O-G Separator Tests 6.4K 20.3K 98.6K -..-	 125.3K 1978 
5. 1.1.3 Sounding Rocket Tests 	 22. 6K 315.5K 472.5K --.- 810.6K 78-79 
5.1.1.3.1 Separator Tests 	 20. OK 312. OK 446. OK .... 778. OK 78-79 
5.1.1.3.2 Freezer Tests (KC135) 2.6K 3.5K 26.5K .-.. 	 32.6K 78-79 
5.1.1.4 Shut+lI Tests 	 152. OK 28.0OK 905K 144. OK -- 1229K 79-83 
5.1.1.4.1 Shuttle Test-Dev. 	 50.0K 10.0K 385K 72.0K -- 517K 79-82 
5.1.1.4.2 Shuttle Test-Proto/Proof 102.0K 18.OK 520K 72.0K -- 712K 82-83 
5.1.2 Equipment Development 304.OK 100.OK -- 50.OK -- 454K 75-78 
6.1 Antibody Prep. Process 	 11. 2K 0. 7K 12.0K -... 23.9K 77-83 
6.1.1 Process Development 	 11.2K 0.7K 12. OK .... 23.9K 77-83 
6. 1.1. 1 Project Supervision 2.2K .. ...... 	 2.2K 77-83 
6. 1. 1. 2 Ground Lab Tests 9. OK 0. 7K 12. OK --.. 	 21.7K 77-83 
6. 1. 1. 2.1 Storage Tests 5.6K 0.2K --.-.-	 5.8K 2Q77 
6.1.1.2.2 Antibody Effectiveness Tests 3.4K 0.5K 12.OK -... 	 15.9K 77-83 
6.1.2 Equipment Development .... 	 .-........
 
Figure I1-lB. Detailed Isoenzymes Research &Development Program Cost-Case A 
WBS TaskTotal 
Task 	 oBS 75 76 77 78 79 80 81 82 83Cost 
1.1 Program Management 347K 12K 16K 23K 76K 69K 32K 54K 39K 26K 
2.1 System Engineering 316K lK 14K 21K 69K 63K 29K 49K 86K 24K 
3.1 Business 	Operations .... .............. ..
 
4.1 Gel Preparation Process 66K .. .. 66K .. .. .. .. .. .. 
5.1 Separation Process 3066K 107K 143K 135K 695K 659K 278K 463K 349K 237K 
6.1 Antibody Prep. Process 24K -- -- -- -- 5K 4K 5K 4K --
TOTALS 3819K 130K 173K 251K 840K 796K 343K 571K 428K 287K 
Figure ItI-2A. 	 Isoenzvmes Research and Development Program (By Year) 
Summary - Case A 
WBS Task 
Total 
otCost 75 767 77 78 79 80 81 82 83 
1.1 PROGRAM MANAGEMENT 347K 12. OK 16. OK 23. OK 76. OK 69. OK 32. OK 54. OK 39. OK 26. OK 
2.1 SYSTEM ENGINEERING 316K 11. OK 14. OK 21. OK 69. OK 63. OK 29.OK 49. OK 36. OK 24. OK 
3.1 BUSINESS OPERATIONS -- -- -- -- -- - --. 
4.1 
4.1.1 
4.1.1.1 
4.1.1.2 
4.1.1.2.1 
4.1.1.2.2 
GEL PREPARATION PROCESS 
Process Development 
Project Supervision 
Ground Lab Tests 
Launch Environment Tests 
Storage Tests 
66.0K 
66, OK 
6. OK 
60.0K 
38.6K 
21.4K 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
66.0K 
66,0K 
6.0K 
60.0K 
38.6K 
21.4K 
-. 
.. 
............ 
.... 
.. 
.. 
. 
.. 
.. 
.. 
...... 
.... 
....... 
...... 
... 
--
--
. 
-­
.. 
-­
4.1.2 EQUIPMENT DEVELOPMENT --. .. .. .. ... ----­
5.1 
5.1.1 
5.1.1.1 
5.1.1.2 
5.1.1.2.1 
5. 1.1.2.2 
5.1.1.2.3 
5.1.1.2.4 
5.1.1.2.5 
5.1.1.2.6 
5.1.1.2.7 
5.1 .1 .2 .8 
5.1.1. 
5.1.1.3.1 
5.1.1.3.2 
5.1.1.4 
5.1.1.4.1 
5,1.1.4.2 
SEPARATION PROCESS 3065. 7K 
Process Development 2611.7K 
Project Supervision 237. OK 
Ground Lab Tests 335.1K 
Enzyme Mobility Tests 1l.IK 
Connection Tests 36. 7K 
Path Length Tests 10.4K 
Path Length-Isoelectric 
Tests 9.4K 
Best Ground Method Tests 51.6K 
Preparative Scale Tests 13. OK 
Environmental Tests 77.6K 
O-G Separator T ests 125 .3K 
Sounding Rocket Tests 810. 6K 
Separator Test 778. OK 
Freezer Test (KC-138) 32.6K 
Shuttle Tests 1229. OK 
Shuttle Tests-Dev. 517. OK 
Shuttle Tests-Prots/Proof 712. OK 
106.6K 142.9K 
52.SK 92.9K 
4.8K 8.5K 
47.8K 84.4K 
11.1K .. 
36.7K .. 
-- 10.4K 
-- 9.4 
-- 51.6K 
-- 13.0K 
-- 77.6K 
...... 
.. .. 
.. .. 
...... 
.. .. 
.. .. 
.. .. 
135.4K 694.6K 659.1K 278. OK 463. 1K 
85.4K 644.6K 609.1K 228.0K 413. 1K 
7.8K 58.7K 52.1K 21. OK 39.1K 
77.6K 125.3K -- - --
.. ............ 
............. 
.. .. .. ...... 
.............. 
.. .. .. ...... 
.... .......... 
.. ............ 
125 .3K --....... 
. 460.6K 850.0K ........ 
.. 428. OK 350.OK ........ 
32.6K --........ 
.. .. 207. OK 207.0K 374.0K 
.. .. 207.0K 207. OK 103K 
.. . -- -- 271. OK 
348.5K 
298.5K 
27. 5K 
--
271.0K 
--
271. OK 
237.5K 
187. 5K 
17.5K 
-­
.. 
.. 
170. 0K 
-­
170. OK 
5.1.2 Equipment Development 454. OK 54. OK 50. OK 60.0K 50. OK 50.0K 60. OK 50. OK 50. OK 50. OK 
6.1 
6.1.1 
6,11.1 
6.1.1 2 
6.1.1.2.1 
6,1.1.2.2 
6.1.2 
ANTIBODY PREP. PROCESS 
Process Development 
Project Supervision 
Ground Lab Tests 
Storage Tests 
Antibody Effectiveness 
Tests 
Equipment Development 
23.9K 
23.9K 
2.2K 
21.7K 
5.8K 
15.9K 
.. 
--
.. 
.. 
.. 
.. 
.. 
..--
--
.. 
.. 
.. 
.. 
.. 
6.4K 
6.4K 
0.6K 
5.8K 
5.8K 
.--
--
--
--
--
. 
4.4K 
4.4K 
0.4K 
4.0K 
--
4. OK 
--
4.4K 
4.4K 
0.4K 
4.0K 
--
4. OK 
--
4.4K 
4.4K 
0.4K 
4.0K 
--
4.0K 
--
4.8K 
4.3K 
0.4K 
3.9K 
--
3.9K 
-­
-­
-­
--
InC, Figure 11-2B. Detailed Isoenzymes Research and Development Program Cost (By Year) - Case A 
(Excludes all tasks associated with establishing process feasibility) 
Cuba Task 
Total 
cost 75 76 77 78 78 80 81 82 83 
1.1 Program Management 125 OK 6.0K 54. OK 39.0K 26. 0K 
2.1 System Engineering 114. OK 5. UK 49. OK 36.0K 24. OK 
3 1 Business Operations - - - - - -­
4.1 Gel Prep. - - - - - -
5.1 
5.1.1 
5.1.1.1 
5.1.1.2 
5.1.1.2.1 
5.1.1.2.2 
Separation Process 
Process Dev. 
Project Supervision 
1104. IK 
904.1K 
89.1K 
-
-
- -55. 
-
K 
5. 0K 
5. UK 
463. 1K 
413. IK 
S9.1K 
348.5K 
298. 5K 
27.5K 
237. 5K 
187. 5K 
17. 5K 
5.1.1.2.3 
5.1.1.2.4 
5.1.1.2.5 
5.1. 1.2.6 
5.1.1.2.7 
5.1.1.2.8 
5.1. 1.3 
5.1.1.3.1 
5.1.1.3.2 
5.1.1.4 
5.1.1.4.1 
Shuttle Tests 
Shuttle Tests - Dev. 
815 OK 
103 OK 
-
-
- - -
. 
-
-­
374. OK 
103.0OK 
271. OK 
-­
170. OK 
5.1.1.4.2 Shuttle Tests - Proto/Proof 712. 0K 271. 0K 271. OK 170. 0K 
5.1.2 Equipment Dev. 200.0K - - - o0K 50. 0K 50.0K 50. OK 
6.1 
6.1.1 
6.1.1.1 
6.1.1.2 
6. 1.1.2.1 
6.1.1,.2.2 
Antibody Prep. Process 
Process Dev. 
Project Supervision 
Ground Lab Tests 
Storage Tests 
Antibody Effectiveness Tests 
8 7K 
8.7K 
0. 8K 
7 9K 
7.9K 
- - -
-
4.4K 
4.4K 
0. 4K 
4.0K 
-
4.0K 
4.3K 
4. SK 
0. 4K 
3.9K 
-
3.8K 
-
-
-
-
-
-
6.1.2 Equip. Dev. - - -
TOTALS 1351.8K 66.0K 570. 5K 427.0K 287.5K 
Figure 111-3. User Isoenzymes R&D Program Costs - Case B 
(Where NASA Establishes Process Feasibility) 
Cubs Task 
Period 
(Years) 
Special 
Skills Materials Services Equipment Faalatin 
1.1 Program Management 75 - 83 Aerospae/Commercial Aerospace contractor/ NIA Conventiong 
Experience integrator 
2.1 System Engineering 75- 83 Aerospace/Commercial Aerospace contractor/ N/A Conetinal 
Experience integrator 
3.1 Business Operations 75 onward Market research N/A Conventional 
4.1 Gel Preparation Process 77 
4.1.1 Process Development 77 Biochemist 
Bio-lab technicians 
Gels, tubes, reagents. 
substrates, photo 
Vibration and shock 
test, Centrifuge 
Electrophoreals apparatus 
storage equipment, Gel 
Biological Lab 
Vibration and abock teat 
supplies, glassware, tests (Johnsville) tube filling equipment facllity, JolWdfle 
stains centrifuge 
4.1.2 Equipment Development 75 - 83 Biochemist same as 4. 1.1 same as 4 1 1 same as 4. 1. same as 4. 1. 1 
Bio-lab technlcians 
5.1 
5.1.1 
5 1,1.2 
Separation Process 
Process Development
Ground Lab Tests 
75 - 83 
?5 - 78 Biochemist same as 4 1. I, plus 
Vibration and shock 
tests, Centrifuge 
tests (Jolnsvillo), 
Electrophoresis apparatus 
(analytical and preparative) 
Biological Lab 
Vibration and Shock Test 
Fpoility. Joine8'itle 
Blo-lab technicians tissue and sera Glass blowing, centrifuge 
Blologieal equipment 
desgn 
Literature search 
Pathologist 
Aerospace payload 
design 
Clinician 
Equipment design and 
5.1.1.3 Sounding Rocket Tests 78-19 same as 5.1.1 2 same as S. 1.1.2 plus 
fabrication 
Sounding Rocket payload same as 5.1.1.2 Payload fabrication and 
payload equip mater-
ials, sounding rocket 
motors 
design and fabrication 
Sounding Rocket launch 
and payload recovery 
test facilities. Sending 
Rocket launch and renew­
cry facilities, Biological 
Lab. 
5.1.1 4 Shuttle Tests 79 - 83 same as 5 i. 1.2 same as 5.1.1.2 plus 
payload equipment 
materials 
Shuttle payload design 
and fabrication, Shuttle 
launch and return ser-
same as 5.1.1.2 Payload fabrication and 
test facilities, Biological 
Lab, Shuttle launch and C 
vices return facilities s 
5.1.2 Equipment Development 75 - 73 same as 5 1 1 2 same as 5.1.1.1 Shuttle payload design same as 5.1.1.2 Payload fabrication and 
and fabrication test facilities 
Biological Lab 
6.1 Antibody Preparation 77 - 82 
Process 
6 1.1 
6 1.1.2 
Process Dvelopmont
Ground Lab Tests 
77 - 82 
77 - 82 same as .1.1.1 same as 5.1 1 2 Cooperating physicians Electrophoreais apparatus Biological Lab 
and clinics 
Conporatig patient 
Freezer equipment 
Assay equipment 
volunteeis 
S 6 1 2 Fquipmont Development 77 - 82 same as 6 1. 1. 2 same as 5. 1.1. 2 None same as 6. 1. 1. 2 Biological Lab 
Figure I-4. Isoenzymes Resources Requirements (R&D) Summary 
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SECTION IV
 
CASH FLOW ANALYSIS
 
The data inputs and parameter values used in the baseline cash flow analysis are shown 
in Figure IV-1. The financial forecast for Case A for the period 1975 to 1992 is pre­
sented in Figure IV-2 A&B. A total market climbing to 50, 000, 000 units per year was 
estimated, with a relatively small market share reaching 10%, on the basis that the 
business would not attempt to address a large share of the market of that size, at least 
initially. The unit price starts out relatively high, but feasible, and reduces over 
time to $6. Lower unit prices in later years appear feasible, judging from the very 
good performance indicators. The Case B forecast is given in Figures IV-3 and 
IV-4 A & B. 
A User-funded research and development program of about $1.4 million (Case B) is 
estimated as required to establish a production capability after demonstration of 
process feasibility. 
Various iterations of throughput and approach were tried in order to establish a baseline 
process which could produce a diagnostic kit for a unit price of $15 initially, with an 
objective of reduction to $6 per kit after wide-scale application of the method. 
IV-1
 
Financial analysis was based on estimation of the following 6 items over a time period 
from 1975 through 1992: 
Total Market - demand for diagnostic kits in the United States, based on the 
assumed existence of 10 relatively high incidence diseases amenable to the 
proposed method of diagnosis. 
Market Share - per cent of total market to be satisfied by the producer, 
based on a gradual buildup to 10% of total market over the time period. 
Unit Price - based on a relatively high initial kit price which is reduced 
to a price near present-day prices for kits of a similar nature. 
Unit Manufacturing Cost - based on an itemization of the process costs to 
produce diagnostic kits, including ground gel tube preparation, in-space 
processing, space charges, ground antibody generation (via horse farm) 
and kit packaging. 
Research and Development Cost - based on an estimate of the ground lab and 
space shuttle/spacelab experiments required to achieve a prototype process 
capability. Case A includes full R&D costs, while Case B excludes the costs 
of demonstrating process feasibility. 
Annual Plant and Equipment - based on equipment and plant expansion or addi­
tion required. A ten-year straight line depreciation was used for purposes of 
simplicity. 
A simplified financial forecast routine was then used to determine the following 
business venture performance measures: 
Percent Return on Investment (ROI) 
This is calculated as annual net profit (after taxes and before payment of dividends) 
divided by net annual investment. The significance of the Return on investment is 
that it indicates the yield to the business after all costs are deducted. It can be 
IV-2 
compared on an annual basis to the return which might be obtained from alternate 
investment of the same funds, including the option of putting the money in a bank 
savings account. The baseline (Case B) ROI obtained is 73% (1992) which is very 
high and suggests that actual results would be lower based on a higher investment 
or lower profit margin due to competitors entering the market. 
Percent Net Income to Sales 
This is calculated as net profit (after taxes and before payment of dividends) divided 
by annual sales. The significance of the Net Income to Sales percent is that it in­
dicates the yield relative to the amount of business (sales) being conducted, for com­
parison with what yield that type of business normally expects to achieve. The figure 
obtained is 21% (Case B) which is well above the pharmaceutical industry figure of 
9.1% (in 1972). 
Cumulative Cash Flow 
This is the summation of the annual amounts of money which must be put into (or 
can be taken out of) the business over the forecast period. Annual cash flows are 
determined as the annual net income after taxes less the annual net change in invest­
ment. The summation of the annual cash flows over time gives the cumulative cash 
flow. In general, the sooner that a business can generate positive cash flow (excess 
cash), the more attractive the venture. In the years when annual cash flow is positive, 
the business is generating more cash than is needed to operate the business. At the 
time when cumulative cash flow turns positive, the business will have paid back all 
of the money put into the business up to that point (breakeven period). The cumulative 
cash flow for Case B turns positive in 1985, 7 years after first expenditures, which 
is an acceptable indicator, considering the long term prospects of the Case B venture. 
Present Value 
Present value is a measure of the worth today of funds expected to be paid out or re­
ceived in the future based on a chosen discount rate. The present value of the business 
IV-3 
is calculated by discounting the annual cash flow at a rate of 10 percent. The net 
annual investment in the last year of the forecast period, which can be taken as a 
measure of the liquidation value of the business, was included in the calculation. The 
baseline present value for Case B is: plus $12M. The significance of the Present 
Value measure is that at zero present value, a businessman is indifferent (theoretically) 
as to whether he puts his money in the bank at interest (at the assumed discount rate), 
or into the business (disregarding business risk). For a positive present value, he 
would rather put his money into the business. 
Constants were established for calculation of costs other than those inputted as shown 
in Figure IV-1 and IV-3. Space charges based on the BUS Phase III cost model were 
included in R&D and production costs. 
The relatively compact, low weight, low energy consumption characteristics of the 
isoenzyrme electrophoretic separation facility make it relatively insensitive to space 
charges compared to other products studied. 
Changes in assumptions could be made to reduce the attractiveness (or increase the 
conservativeness) of this conceptual venture: 
Decrease unit price 
Increase unit manufacturing cost 
Increase other operating expenses 
Decrease market share 
Increase investment 
On the optimistic side, assuming the total market is valid, the market share is very 
conservative. An increase in market share would improve overall venture attractiveness. 
IV-4 
8/6/75
 
INPUTS: 75 76 77 78 79 A 81 82 83 84
 
TOTAL MANK5T (ITS 
 . :. . . ;.20COO0.CtOCOc.2Ooo0000000.20000000280000000.
MANKET SHARE (PCT) 3. .
 , , .. 0. 0. 2. 4. 5v
UNIr PRICE C. .o 
 0. C. C. 
 0. 0. 15. 15. 15.
UNIT MANUFACTuRING c2sr *00 
 o.3 ,03 
 .00 ,00 6.00 6.00 6.00
R AND 0 EXPENSr 133 03. 17300C. 2 1 3., d4530. 
7q62 03. 343000. 571C03 428000, 287000a o
ANNUAL PLANT AN3 E-jIP. 

. C.75333, 
 6'0000. 96000. 0. 0 t280000,
 
INPJTS: $5 86 7 A8 A9 9c 91 92 
 93 94
 
TOTAL AKKET (uNITS) 

.453O0O05C0330.500OO0 
 0. JCC3D.2OCZ0CC.42CZZ'0.:02dC0.43030C0
O
MARKET SHARE (pCT) 6' 6. 
 7. 7. d. 8. 
 8. 10, 0. O.
UNIT PRICE 13 15. 14. 13. 
 1c. 9. 8. 6. 0. 0,
UNIT MA1,UFACTu-Ir CYST b.33 5.3: b.30 5.3C 
 4.53 4.00 3.00 2.53 .00 .00
R AND 9 EXPENSE 3. 2. 0. 3, 
 0. 0, 0. 0. 0. 0.
ANNJAL PLANT AN' ECLIP. 8 Joo0, 
 3000.2. t48300. 533000. 0. 0. 0. 0. 0.
 
PARAMERIC PERCENTAGES:
 
PARAMETER I:ENTIFIE4 VALJE PARMETER 
 IDENTIFIER VALUE

INTEREST kATE 
 '11 103,0 JITS MAkJFACTURE) PrT. P2l 120.00
AVERASE I'JVENOTRY oct. 
 Pd3 .33 E.%GINEE;IG EXPENSE PCT. P26 
 5.00SELLIN3 EXPE',S- PCT. 027 5.3r APr[NISTFATI3N EXPENSE PCT D28 10.00 CNECEISAtLES hCT. PS= c0.:3 :EPPECIATIrN PEr)O(YRS) P35 10.00
 
5TNER INVLSTEmNT OCT. P36 5-

PERCENTAGE jF n4SELINt SL2 
 A)C/SJS FAQ" SASELTNE INPJTS
 
INPUTS IE\TIfrIEq OCT tENTIFrER VALUE

TOTAL MARKET Xl 130 At 
 0.
MARKET SARE XE 1 3 
 42 0.
 
UNIT PqICE 13 A3 
 .00
 
UNIT "A\JFACICQ1I.3 C9 rTs 
 44 0.
ANO '0LXPEqSE X5 1As 0,
ANNUAL PLANT A'4, E1~iP. X6 120 A6 0. 
Figure IV-1. Isoenzymes Input Values - Case A ci 
8/6/75
 
75 76 77 78 
 79 80 81 82 83 84
 
IBTAL MARKET (U\ITS) 0. 0
o. . 0. POoo000.
MARKET SHARE (POT) .,o 20000000. 20000000. 20000000. 20000000.
.,Jo .00 .00 .00 .00 
 .00 2.00 4,00
ONITS SOLD (UNITS) 
,. J3 0, 0. 5.00 0. 0.
UNIT PRICE 0. 0. 400000. 800000, 1000000.
u. 0. 0. 0. 0. 0.
SALES 15. 15. Is.
0. 0. 0. 0. 0. 0.
UPERATING EXPENSES 0. 6000000, 12000000. 15000000.
130000. 173000. PLO00°. 840000. A71000.
GRUSS PRUFITS 478000, 804000. 4273000. 7744000. 9391000.

-130000. -1730ou. -P51000. 
-840COO. 
-871000. 

-478000. 
-804000. 1727000,
ANNUAL INVESIMENI 4256000. 5609000.
0.
,. 0. 0. 67000o. 1140000, 1887000. 3130000.
CUMULATIVE GOSS PROFITS 
-130000, 4373000. 6030000.
-30300U, 
-554003. 
-1394C00. 
-2265000. 
-2743000. -3547000. -1820000.
bASE FOR INTEREST EXP. 2436000. 8045000.
130000, 303000. 5O000. 1394C00, 2940000. 38R3000, 5434000. 4950000.
INTEREST EXPENSE 1937000, 0.
13000. 30300,. 55402. 139400. 294000, 388300. 543400. 495000,
INCOME BEFORE TAXES 193700. 0.

-143000, 
-203300. 
-306400. 

-979400. 
-1165000, 
-866300. 
-1347400. 1232000,
TAXES 4062300. 5609000.

-68640, 
-975Rq. -147372. 
-470112. "b59200. 
-415824. -646752.
NET INCOMF ALTER TAXES 591360, 1949904. 2692320.
-74360. -105716, -159328. -50q288- -605800. 
-450476. 
 "700648. 640640, 2112396.
NET CHANGE IN INVEST. 0. G. 0. 2916680.
 
ANNUAL CASH FLUw 
0. 675000. 465000. 747000. 1243000. 1243000. 1657000.

-74360. 
-105716. 
 -359328. 
-509288. -1280800. 
-915476. 
-1447648. -602360.
CUMULATIVE CASH FLO. 869396. 1259680.

-14360. 
-180076. 
-339404, 
-848692. 
-2129492. 
-3044968. 
-4492616. -5094976, .4225580o -2965900.
8ETURN ON INVEbTMENT(PCT) .00 
 ,00 .00 .00 
 -89,75 
-39.52 -37,13,
NET INCOME Ti 20.47 48.31 48.37
bALES (POT) .00 .00 -00 .00 
 .C0 .00 
 .00 10.68 17.60 19.44
 
O P E R A T I NG E X P E N S L
 
UNIT MANUFACTURING C9ST 
 .00 .00 .00 
 .00 "00 -CC
UNITS MANUFACTURED(U&ITS) 0, U, .00 6.00 6.00 6.00
J. 0. 0,
LUST OF 5OS MFG, 0. 0. 480000. 960000. 1200000.
0. U.0. 
 0. 
 r, 0 0. 2880000. 5760000. 7200000.
AVERAGE INVENTORY... 
 2. 0.
0, 
 0. 0, 0.
N AND 0 EXPENSE 130000, 173000. P51000, 0. 576000, I52000. 1440000.
840CO0, 796000. 343000. 571000. 428000.
hNbINEEPRI, EXPENSE 287000. 0.
0. . 0. . O.0  0. 144000. 288000. 360000.
SELLING EXPENSE 
 Q,. 0, 0, 0. 0. 0,
AUMINISTHAtIUN EXPENSES 300000. 600000. 750000.
0. O. 0, O. 0. 0. 
 0. 288000. 576000.
DEPRECIATIeN EXPENSES.. 720000.
0. J. 
 0. O. 75000. 135000. 233000- 233000.
TOTAL OPERArIN6 EXPENSES 233000. 361000.
13G000. 173000, 251000. 840000. 
 871000. 478000 
 804000. 4273000. 7744000. 9391000.
 
1 N V L b T T
 
NECEIVABLES (AVGs) 
 J. 0. 0.
INVENTORIES (AV) 0. U, 3. 0. 0. 1200000. 2400000. 3000000.O. 0. 0.
ANNUAL PLANT 0. ,576000, 1152000. 1440000.
AND EQUIP* 0. 
 O. 0. 0. 750000. 600000. 980000.
CUMULATIVE PLANT - EOUIP, 0. 0. 0. 0. 1280000. ANNUAL DEPRECIATION 0. 0. 0. 750000. 1350000. 2330000. 2330000 2330000. 3610000.
U, 0. 0. 75000. 135000 233000. 233000. 233000. 361000.
CUMULATIVE QEP4ELIATIUIN 3. .
 0. 0. 75000. 210000 443000. 676000. 909000.
NET PLANI + ECUIP 1270000.

. 0. 0. 675000. 1140000, 1887000. 1654000. 
1421000. 2340000.
UTHER INVESTMENT... 
 0. 0,

NET ANNUAL INVESIMENT 0 0 0. O. 0. 300000. 600000. 750000.
0, J. 
 3. 0. 675000. 1140000. 1887000. 3130000, 4373000. 6030000.
PRESENT VALUE UF ANNuAL CASH FLOw 
 10754509.
 
* ASSUME TAX LOSS IS C-EOITED AGAINOT JTNE? 3JSIES INCOME.
 
THIS ITEM 
IS \ORMALLY INCLJ)EO I'.VARIOUS SVE.*HEAU ACCOJNTS.
INVENTORY OENIVATIMN IS W.IHLY SISPLIFTLO, B,,T APPR9XIMATES MORE rOMPIEX METHOJS
 
.... INCLUDES MISC. LIABILITIES SUC, 
AS ACCOJNTS PAYASLE, RESERVES, SUNoRY rREDITOi ITEMS 
Figure IV-2A. Isoenzymes Cash Flow Analysis - Case A 
8/6/75 rASE: 
53 86 7 8 .9 90 91 92 93 94 
rTrAL MARKET (UNITS) 200000C a5OOOV. 300"000. 35000000. 40000000. 45000400. 500C0000- 50000000. 
MARKET SHARE (PCT) 6-00 6.U3 6,7C 7.10 7.;O 7.80 9.0C 10.00 
UNITS SOL, It iTm) 1230000. 150003u,. 201300, 2485C00, 3)00000. 3510030, 4000000. 5000000. 
JNIT PRICE 1D. 1. 14, 13. i. 9. 8. 6. 
bALEb 180000. 22500030. P8140000, 32305000. iOCO00CO. 31594030. 32000000. 32500000. 
UPLRATING LXPENSLS 10122800, 12592030. 16634143. 20434540. 20749000. 21513730. 18621000. 19336000. 
URUSS PROFITS 7A7/200. 3908G0.. 11535660. 1197C460. 9251000. 10076300. 13379000. 13164000. 
ANNUAL INVLSI-Ni 6970400. 303100.J 912912,3 11094670. 10709000, 10516100 9629000. 9363000. 
LUMULATIVE 5RO95S PPOFITS 15922203. ?583023-., 37356060. 49236520. 58487!,20 68563820, 81942820, 95106820. 
BAbE FOR INTL4iST EXP. G. J. 3. 0. 0. O' 0* 0. 
INIEREST EXPLNSE C. u. 0, 0. 0. 0, 0, 0. 
LNCOsE ULFORL TAXES 7877200. 9980C3- 11535660, 1187%460. 9251000. 10076330 13379000. 13164000. 
TAXES 3761056. 4755840, bE37213. 5697821. 4440480. 4836624. 6421920. 6318720. 
NET INCOME AFTER TAXES 4D96144. 1S215u, 599,1647, 6172639. 4810520. 5239676, 6957080. 6845280. 
NET LHANGE IN I\VEST. 940400, 1060610. 998720. 2064950. -385670. -190900. -889100. -266000. 
ANNUAL CASH FLBU 315b7.4, 4091b6," 4999927. 4107689, 5196190. 5430576. 7846180. 7111280. 
LUMULATIVE CASH FLO. 189844. 4281404. 9281331. 13389C20. 18b85210. 24015786. 31861966. 38973246. 
RETURN ON INVEbTMENT(PCT) 58.76 64.15 66.43 95.64 44.92 49.82 72.25 73.11 
NIT INCOME TB SALES (PCT) 22.76 22.30 21,32 19,11 16.04 16.59 21.74 21.06 
0. 
.00 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
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0. 
.00 
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0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
.00 
.00 
b P E R A TI N G EXPENSE 
UNIT MANUFACTURI.G C5ST 
JNITb MANUFACTURED(ULNITS) 
C~bT UF G080b MrU. 
AVERAGE INVLNTURY'.. 
q AND D EXPENSE 
NbINEEPIb LXPE.SE 
bELLING EXPENSE 
AOMINISTRATION EXPENSES 
JERECIATIBN EXL'SES*' 
[IAL 8PERATINg EXPENSES 
b.30 5.33 
14000. 180OOu. 
763e000. 3540005. 
1526400. 1908000. 
0, j. 
381600, 477CCJ. 
900000. 112bOC.) 
763200. 95400,. 
446000, 496000. 
1012d800, 1259203u 
b.30 5.30 4. 0 4.00 
?412000. 298C00. 3600000. 4212000. 
12733600. 15804600. 16200000. 16848000. 
2556720. 3160920. 3240000. A369600, 
s. 0. 0. 0. 
639160. 790230. 81000. 842400, 
1407000. 1615250. 1500000. 1579500. 
178360. 158,460. 1620000. 16g4800" 
.96300. 644000, 619000. 559000. 
16604140. 20434540. 20749000. 21513700. 
3.00 2.50 
4800000. 6000000. 
14400000. 15000000. 
2880000. 3000000, 
0. 0. 
720000. 750000. 
1600000. 1625000. 
1440000. 1500000. 
461000. 461000. 
18621000, 19336000. 
.00 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
.00 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
I N V E b r E 4 T 
RECEIVA8LES (AVG) 3600000. 
INVENTORIES (AVO,) 1526400. 
ANNUAL PLANT AND EgjIP" 850000. 
LUMULATIVE PLANT + EtUIP. 4460000. 
ANNUAL DLPRECIATjON 446300. 
CUMULATIVE OLEPRECIATIbN 1716000. 
NET PLANT + EUIP , 2744000. 
3IHER INVESTMENT*"'* 300300. 
NET ANNUAL I1VLEFSENT 697U400, 
PRESENT VALUL UF ANNUAL LASH FL5S 
4500030 5628000. 6461000. 6000000. 63180300 
1909O00. 28,56723. 316920. 3P40000. 3369600. 
500C30" 0. 1480000, bOOOOO. 0 
490UZ' 496000,. 6440000. 6940000. 6940000. 
49630, 496000, 64400. 619000. 559000. 
22120.- 2708003. 335PC00 3971000. 45300D0 
274830. 2052000, 3088000. 2969000. 2410000. 
1125300. 140COO0. 1615250. 150000. 157950G. 
6031000, 932972, 11094670. 10709000. 10518100 
IO7o4509. 
6400000. 
2880000. 
0. 
6940000. 
461000. 
4991000. 
1949000. 
1600000, 
9629000. 
6500000. 
3000000. 
0. 
6940000. 
461000. 
5452000, 
1488000. 
1625000. 
9363000. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
0. 
AS60ME TAX LUSS IS CqR.IlE2 AOAINST ST-- .AI'ESS IICSME, 
THIS ITE IS '\bRALLYINC(JDE0 I. ARIS9b 9VEHEAD ACCOUNTS. 
*f0 INVENTORY UEMIVATIt I .I93LY bIMPLIFI09, BiT APPROXIMATES 'fRE ruMPIEX METH5DS 
**. I\CLJOES MhIC, LIA3ILITIES SUCH AS ACCt\TS PAYAiLE, RESFRVES. SJNDFSY CRE0IT3, ITEMS 
Figure IV-2B. Isoenzymes Cash Flow Analysis - Case A 
8/6/75 
INPUTS: 75 76 77 78 79 AO 81 82 83 84 
TOTAL MARKET (UNITS) 0. a. 0. 0. 0.20000000?.OOOOOOO20000000200000 00 . 2 00 00 00 0 
MARKET SHAkE (PCT) 0. a. 0. 0. 0. 0. 0. 2, 4* 5, 
UNIT PRICE 0. 0 0. a. a. 0. 0. 15, 15. 15. 
UNIT MANUFACTURING COST .00 *00 .00 OC' .00 .00 .00 6.00 6,00 6,00 
R AND D EXPENSE 0. 0. 0. O, 0. 66000. 571000. 428000, 288000. 0. 
ANNUAL PLANT AND EQUIP. 0. . 0. 0. 750000. 600000. 980000. O 0. 1280000, 
INPUTS: 8b 86 R7 RR R9 9O 91 92 93 94 
TOTAL MARKET (UNITS) 20000000.2500000030000000.35000000,400000005.4o00000.50000000.50000000, 0. 0, 
MARKET SHARE (PCT) 6. 6, 7. 7 , a. 8. 8. 10, 0. 0. 
UNIT PRICE 15- 15, 14. 13. 10. 9, 8. 6. 0. O, 
UNIf MANUFACTURING COST 
R AND 0 EXPENSE 
b.30 
0. 
5.30 
0, 
5.30 
0, 
5.30 
0. 
4,50 
0. 
4.00 
0. 
.3.00 
0. 
2.50 
0. 
.00 
0. 
.00 
Dt 
ANNUAL PLANT AND EQUIP- 850000. 500000. 0. 1480000. 500000. 0. 0. 0. 0. 0. 
PARAMETRIC PERCENTAGES: 
PARAMETER IDENTIFIER VALJE PARAMETER IDENTIFIER VALUE 
INTEREST RATE P11 10.00 UNITS MANUFACTURED PrT. P1 120.00 
AVERAGE INVENTORY PCT. P23 4000 ENGINEERING EXPENSE PCT- P26 5.00 
SELLING EXPENSE PCT. P27 S.00 ADMINISTRATION EXPENSE PCT P28 10,00, 
RECEIVABLES PCT. P31 20.00 DEPRECIATION PERIQD(YRS) P35 10.00 
vo OTHER INVESTMENT PCT. P38 5.00 
I PERCENTAGE OF BASFLINE USED ADD/SUB FROM BASFLTNE INPUTS 
INPUTS IDENTIFIER PCT IDENTIFIER VALUE 
0 
TOTAL MARKET 
MARKET SHARE 
Xl 
X2 
100 
100 
Al 
A2 
0. 
0. 
UNIT PRICE X3 100 A3 .00 
UNIT MANUFACTURING COST X4 100 A4 0. 
R AND D EXPENSE X5 100 AB 0. 
ANNUAL PLANT AND EQUIP. x6 100 A6 0. 
Figure IV-3. Isoenzymes Input Values - Case B 
8/6/75
 
75 76 77 78 T9 
 80 81 82 
 R3 84
 
TOTAL MARKET (UNITS) Q. 
 0o. a. o. POOOOCo. 2ooOOoo. 20000000. 20000000. 20000000.
MARKET SHARE (PCT) .00 
 ,O ,00 ,OD 
 .00 .0c .O P.0O 4.00 ".00
UNITS SOLD (UNITS) 0. u. 
 0. 0. 0. 0.
UNIT PRICE 0. 0. 0. 406000. 800000. 1300000.
0. 0. 0. 
 0. 15. 15. 15.
SALES 
 0. U. . 0. 0. 0. 0. 
6000000. IP00000. 15000000.
OPERATING EXPENSES 
 OA 

GROSS PROFITS 
U. 0. 0. 75000. 201000. 804000. 4273000. 7745000. 9391000.
0. . 0, 0. -75000 -201000. 
-804000. 1727000 4255000. 
5609000.
ANNUAL INVESTMENT 0. 
 Q. 0. 0. 
 675000. 114000. 187000. 3130000. 4373000. 6030000.
CUMULATIVE GROSS PROFITS 
 0* .
 0. 0 -75000. 
-276000. -1080000. 647000. 4902000. 10511000.
BASE FOR INTEREST EXP. 0. 
 ., 0. 0, 7E0000. 14t16000. 2967000. 2483000. 
 0. 0.
INTEREST EXPENSE 
 0. 0. 0. 75000. 141600. 296700. 248300. 0.
INCOME BEFORE TAXES 0.
0. 0. 0. 
 0. -150000. 
-342600. -11007U0. 1478700 4255000. 5609000.
TAXES 
 0. U. 
 0. 0. -72000. 
-164448. -528336. 709776. 2042400.
NET INCOME AFTER TAXES 2692320.
0. 0. 1. 
 0. -78000. 
-178152. -572364. 768924. 2212600. 2916680.
NET CHANGE IN INVEST, 0. 0. 0. 
 0. 675000. 46bOOD. 747000. 1243000. 1243000. 1657000.
ANNUAL CASH FLOW 
 0. 0. 0. 0. -753000. -643152. 
-1319364. 
-474076. 969600. 1259680.
CUMULATIVE CASH FLOW 
 0. 0. 
 0. 0, -753o O. -1396152. -2715516. .3189592. -2219992. -960312.
RETURN ON INVESTMENT(PCT) .o 
 .00 .00 .00 -11.96 -15.63 -30.33 24.57 
 50.60 4A.7
NET INCOME TO SALES (PCT) .00 .0O ,00 
 .00 .00 .00 .00 
 12.82 18.44 19.44
 
OPE RAT ING EXPENSE
 
UNIT MANUFACTURING CSST .00 . .00 00 .00 .00 .00 .00 6.00 6.00 6.00
UNITS MANUFACTURED(UNITS) 0. 0. 3. 
 0. .. 0. 
 0. 480000. 960000. 1200000.
 
AVERAGE INVENTORY... 0. 0. 0. 

COST OF GOODS MFG- 0. 0. J. 0. 0. 0. 
 0. 2880000. 5760000 7200000.
0. 0. 0. 0. 
 576000. 1152000. 1440000.
R AND D EXPENSE 0, U, 3. 
 0. 0. 66030. 571000.
ENGINEERING EXPENSE 428000. 288000. 0.
0, . 0. 0. 
 0. 3. 0. 144000. 288000. 360000.
SELLING EXPENSE 
 0. 0. 3. 0. 0. 0. 0.
ADMINISTRATION EXPENSES 0. 0. 0, 0. 0. 
300000. 600000. 750000.
0. 0. 288000. 576000. 720000.
DEPRECIATION EXPENSES.-
 0 U. 0. 0. 75000. 135030. 233000. 233000. 233000. 361000.
TOTAL OPERATING EXPENSES 
 0. 0. 
 0. 0. 
 75000. 201000. 604000. 4273000. 7745000. 9391000o
 
I N V E S T M E N T
 
RECEIVABLES (AVG) 0. 0. 0. 
 0. 0. 0' 0. 1200000. 2400000. 3000000,
INVENTORIES (AVG) 
 0. . 0). 0. 0. 0. 0.ANNUAL PLANT AND EQUIP. 0. 0' 0. 576000. 1152000. 14400o0.
0. 790000. 600000. 980000.
CUMULATIVE PLANT * EQUIP. 0. 0. 0. 0 12COOO.
0. 0. 750000. 1350300. 2330000. 2330000. 2330000. 
 3610000.
ANNUAL DEPRECIATION 0, 0, 0. 0. 
 75000. 135030. 233000. 233000. 233000, 361000,
CUMULATIVE DEPHECIATION 0. U. 0, 0. 75000. 210000. 443000. 676000. 909000. 1270000.
NET PLANT + EQUIP. 0. 
 U,. 3. . 67o000, 1140000. 1887000, 1654000.
OTHER INVESTMENT*... 0. 0. 1421000. 2340000,
0. 0. 0. 0.
NET ANNUAL INVESTMENT 0. ). 0, 3. 3COOOO. 600000. 750000.
0. 675000. 114CO00 1887000. 3130000. 4373000. 6030000.
PRESENT VALUE OF ANNUAL CASH FLOw 12153861.
 
* ASSUME TAX LOSS IS CREDITEC AGAINST OTHER SUSIESS INCOME.
** THIS ITEM IS NORMALLY INCLUDED IN VARIOUS OVERHEAD ACCSJNTS.
 
INVENTORY DERIVATION IS HIGHLY bIMPLIFIEj, BUT APPROXIMATES MORE C-3PIEX METHoaS

* INCLUDES MISC. LIABILITIES SUCH AS ACCOUNTS PAYA-LE, RESERVES, SJNDRY rREDtTS? ITEMS
 
Figure IV-"4A Isoenzymes Cash Flow Analysis - Case B 
Y
 
8/6/75 CASE: 
t5 86 '7 88 '9 90 91 92 93 94 
ibTAL MARCET (UITS) 20000000. 260000C3. 3003000. 3bO00CCO. 40000000. 45000000, 50000000. 50000000. 
MARKET SHARE (pCr) 6.00 1-J' 6.70 7.10 7.50 7,80 8.00 10.00 
UNITS SOL' (UNITS) 1?000)0. 150003,. 2 10000. 2485CO0. 3000000. .85I0000. 4000000. 5000000. 
UNIT PRICE 15. 1,. 1i. 13. Ic. 9. A. 6. 
bALES 18000000, 2250000U, 28140000, 32305000, 3O00000 31590000. 32000000. 32500000. 
UPERATINb EXPENSES 10128800. 12592000. 16604140. 20434540. P0749000. 21513700. 18621000. 19336000. 
GNSS PRBFITS 7877200, 990800 . 11535863, 11870460. 9251000. 100;63JO 13379000. 13164000. 
ANNUAL INVESrfO-. T 6970400. 803100. 9129720, 11094670, 10709000. 10518100. 9629000 9363000. 
CUMULATIVE GROSS PROFITS 1838b200. 2829620U. 39832060, 5170P520. 60953520, 71029820. 84408820. 97572820 
OAbE FOR INTEREST EXP. Q. . 0, 0. 0. 0. 0, 0 
INIENEST EXPENSE 0, 0. 3. 0, 0. 0. 0. 0. 
INLaOL BEFURt FAXES 787720o, 990500u, I535860, 11870460. 9251000. 10076430. 13379000. 13164000. 
AXEb 3781056. 4755840. 5937213, 5697821. 4440480. 4836624. 6421920. 6318720. 
NET INCOME AFTER TAXES 4096144, ,15216, 5998647, 6172639. 4hI0520, 5235676. 6957080, 68465280. 
NEr CHANGE IN I\VEST. 940400, i060630. 998720. 2064950. -385670. -190930. -889100. -266000. 
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Figure IV-4B. Isoenzymes Cash Flow Analysis - Case B 
The further analysis of the concept and of these areas for increasing or decreasing 
conservatism are beyond the scope of this study. However, the possibilities are 
presently very encouraging and early ground lab studies of the process phenomenology 
are highly recommended. 
Figure IV-5 presents a plot of the key financial measures for the Isoenzyine product. 
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Figure IV-5. Isoenzymes Cash Flow 
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SECTION V
 
MARKET ANALYSIS
 
V. 1 INTRODUCTION 
The market addressed is that for diagnostic kits sold to physicians and clinics, for 
use in diagnosis of up to 10 diseases, none of which can be given early or accurate 
diagnosis with presently available methods. The period of interest is 1980-1992. 
The specific diseases and kit antibodies are undefined (creatine kinase and glycogen 
phosphorylase are candidates) and are to be selected during the development program 
which extends from 1975-1982. The space product, which makes the diagnostic kit 
feasible, is a set of up to 10 antigens which are obtained via gel electrophoresis on a 
preparative scale (in the concept used, one 5 cm diameter x 220 cm length gel tube 
provides 0. 1 gram of purified antigenic protein which is specific for one disease state). 
While disease treatment may be a future capability, the market forecast is limited for 
the present, to demand for diagnostic purposes only. 
Virtually no precedent exists for forecasting of kit demand and kit price, and so the 
forecasts given here must be used with caution. 
A conceptual description of the business which would address the market of interest 
is given in the following paragraphs. 
V. 1. 1 ORGANIZATION 
The Business is established as a product line under a product manager in the house of 
an existing manufacturer of biologicals. An on-going association has been formed by 
the manufacturer with one or more hospitals and clinics for the testing, certification, 
and introduction of space-processed isoenzyme products. The roughly one to five 
million diagnostic kits produced per year are marketed via an expansion of the existing 
sales and distribution channels of the manufacturer. 
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V.1.2 FACILITIES AND EQUIPMENT 
New facilities, associated with the existing plant, have been prepared for preparation 
of gel tubes, quality control, and flight preparation of the space isoenzyme separation 
facilities. Equipment for gel preparation, tube loading, space facility loading, etc. 
has been installed, mostly of conventional design. Gel preparation facility capacity 
is in the order of 1 to 4 hundred large (5-8 cm diameter) tubes per year. 
Space processing facilities (2 or more units) are maintained for in-space electro­
phoretic separation of isoenzymes, using Shuttle transport and in-orbit services. 
The isoenzyme/antibody preparation facility is equipped with conventional gel tube 
handling, gel removal, slicing, etc. equipment for preparation of animal injections 
of the antigen. An animal farm, probably a horse farm of 100 or more horses is 
maintained for growth of antibodies. Periodic blood drawings from the ammals are 
processed at a facility which is equipped with conventional equipment for preparation 
of gamma globulin.fractions and preparation of the diagnostic kits which constitute 
the finished product. 
V.1.3 INITIAL R&D 
To reach production status, the Business has incurred a significant expense in research 
of candidate isoenzymes, gel preparation and electrophoresis techniques, and facility 
development, both ground and in-space, to reach full scale production capability. This 
investment is taken as $1. 4 million, (Case B), spread over 4 years after government­
funded demonstration of process feasibility. In association with hospitals and clinics, 
the Business has conducted an extensive test program using experimental products to 
establish the marketability and high level (90-95%) effectiveness of the diagnostic kits 
in diagnosis of diseases. 
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V.1.4 CONTINUING R&D
 
The Business maintains a continuing engineering (product and process development)
 
program of 5% of sales to assure a competitive selection of isoenzyme products.
 
V. 1.5 SPACE SHUTTLE SERVICES 
Arrangements have been made with NASA for regular (say monthly) shuttle services, 
including up-transport, on-orbit operations in low earth orbit, and down-transport 
services. On-orbit operating times are 7 days or more per flight. The procedures 
for using shuttle services will have been established during the R&D phase, and ser­
vice charges, legal considerations, schedules, etc. will have been agreed to and 
documented. 
V. 1. 6 INVENTORY AND RECEIVABLES 
The Business operates at a relatively even month-to-month production level. Inventory 
is maiftained on an annual basis of 20% of sales, and Receivables average 20% of sales. 
V. 2 PRODUCT BENEFITS 
The benefits of the new antigen/diagnostic kit are the early and accurate diagnosis of 
disease states. A low kit price would allow screening of general populations in addi­
tion to the specific diagnosis of suspected cases. Early diagnosis would mean more 
time for specific treatment and a higher patient recovery rate. Accurate diagnosis 
(virtually no false positives and no false negatives) would allow avoidance of unneces­
sary treatment, concentration on specific curative treatments, and an intangible benefit 
in the form of patient peace-of-mind. A long range benefit (not pursued in this market 
analysis) is that of specific disease treatment of diseases which presently lack effec­
tive curative methods. 
V.3 COMPETITIVE PRODUCTS AND COMPETITORS 
The only present competitive products are those antigenic proteins which are available 
for just a few diseases. These products are relatively impure, thus lacking specificity 
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and giving an undesirable number of false positive diagnoses. When available, the 
space-processed product will most likely have no competitor with the equivalent 
specificity. 
V. 4 POTENTIAL ALTERNATIVES 
No presently identifiable alternatives exist for the diagnostic capability proposed. 
No ground-based equivalent exist for the isolation of purified isoenzymes. Although 
much work is being done in this area, there is no reason to expect the development of 
a ground-based process which will accomplish what the space process may achieve by 
virtue of zero-G operations. 
V. 5 MARKET FORECASTING 
The market has been forecast on the bqsis of low-priced Idts being made available, 
and that selective screening followed by widespread screening in theoU. S. only is 
conducted under government or other auspices. Assume a U. S. population of interest 
of 200 Million persons, and 10 relatively high incidence diseases, each of which has 
an incidence rate of 170. The incidence for these 10 diseases is then (10 x 0. 01 x 
200, 000, 000) or 20, 000, 000 cases. If the discovery rate is one diseased patient in 
every 5 examined, 100 million diagnoses would be required to identify all diseased 
patients. Assuming a 5-year selective screening program, a demand for 20 million 
kits per year is obtained, for the U.S. only. A subsequent general screening program 
for the total population yields a demand for 50 million kits per year. (20, 000, 000 cases, 
discovery rate one in twenty, 8 year program). Recognizing a gradual building, de­
mand would increase from 20 million kits in 1985 to 50 million by 1992. 
Extrapolation of this basis to the world demand would, of course, generate huge num­
bers. In summary, a demand of 20-50 million diagnostic kits for the total demand 
1980-1992 appears conservative, and is presented as follows. 
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Year Kits (millions) Year Kits (millions) 
1980 20 1986 25 
1981 20 1987 30 
1982 20 1988 35 
1983 20 1989 40 
1984 20 1990 45 
1985 20 1991 50 
1992 50 
Figure V-i. Demand for Diagnostic Kits, 1980-1992 
V. 6 PRODUCT QUANTITIES AND PRICING 
The forecast of market share in terms of units sold is based on successful isolation 
of at least several of the 10 desired iscenzymes and successful satisfaction of about 
8% of the demand given in paragraph IV. 5 by 1991, giving a sales forecast as follows. 
Year Sales (kits) Year Sales (kits) 
1980 1986 1500K 
1981 - 1987 2000K 
1982 400K 1988 2500K 
1983 800K 1989 3000K 
1984 1000K 1990 3500K 
1985 1200K 1991 4000K 
1992 5000K
 
Figure V-2. Sales Forecast (Diagnostic Kits) 1980-1992 
A price per kit of $15 is estimated for the 1980-1985 period, with a drop to $6 per kit 
by about 1992 as part of the market expansion to include general population screening. 
V. 7 PRODUCT LIFE CYCLE 
The introduction and growth phases of the product life cycle will probably be produc­
tion hinted, as well as being paced by the degree of success in working with physicians 
and clinics to establish confidence. Product decline and exit would be attributable to 
the arrival of a much cheaper (e. g., ground processed) alternate diagnostic tool. 
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However, addition of new isoenzymes to the product line could easily extend the product 
life cycle beyond that shown below. 
Phase From (year) To (year) 
Introduction 1980 1983 
Growth 1984 1991
 
Maturity 1991 1999 
Decline 1999 2009 
Exit 2009 2019 
Figure V-3. Isoenzyme Diagnostic Kit Product Life Cycle 
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SECTION VI
 
COST/VALUE FOR PRODUCTION
 
VI. 0 ISOENZYME PROCESSING 
This section presents the baseline production concept for producing isoenzyme-diag­
nostic kits, along with the assumptions and key findings for the product venture. It 
must be remembered that all figures given here are conceptual only, and are subject 
to change upon further and more detailed investigation. 
VI. 1 FLIGHTS AND RESOURCES REQUIRED FOR PILOT PLANT AND FULL SCALE 
PRODUCTION 
The isoenzyme production process presents a sequence of ground-space-ground 
process steps with one in-space process step required, that of zero-g electrophoretic 
separation. A throughput analysis, unit product cost breakdown, and rough break­
downs of associated costs are provided in the following paragraphs. 
VI. 	1. 1 ANALYSIS OF PRODUCT VOLUME AND TIME VS. PAYLOAD CAPACITY 
AND TIME 
The forecasted manufacturing volume is an initial output of 400, 000 kits in 1982, 
building up to a level of 5 million kits per year in 1992. The 1982 start implies the 
start of small scale production while the R&D program (which ends in 1983) is still 
in process. The small quantities of space-processed product required for 400, 000 
units of output makes this a reasonable possibility. The electrophoretic separator 
envisioned would process 600 milligrams of protein per 7-day flight, which equates 
to about 120, 000 diagnostic kits. Thus, in the first year of production, about 3-4 
flights of one separator would suffice, or a single 7-day flight with 4 separators would 
accomplish the same purpose. At full scale production of 5 million kits per year, 
10 flights per year with 4 or 5 separators aboard would be sufficient. The electro­
phoretic separator would be a relatively compact, modular unit, so that flights of 
multiple separators would appear to be straightforward. Another possibility would be 
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to scale up the baseline separator for larger throughput (larger tubes or plates), so 
that no payload capacity problem appears likely. A throughput analysis for the space 
process and ground process steps is shown in Figure Wl-1, for an annual throughput 
of 1. 2 million units. 
VI. 1. 2 ANALYSIS OF PROCESSING SUPPORT REQUIREMENTS VS. SHUTTLE/ 
SPACELAB AVAILABLE RESOURCES 
The electrophoretic separator is conceived as being self-contained in terms of gel 
tube storage, and buffer and coolant supplies, so that the only support requirements 
would be for input power and crew attention. The separator would operate on a 
nominally 24-hour cycle, with say, 6 tube separation cycles per 7-day flight. 
Operator duties would be to install the gel tube, (taken from freezer storage) initialize 
the process controls, and monitor the process by periodic observation of a meter or 
fault indicators. An average of one man hour.per day of crew support is estimated. 
A single separator power requirement is roughly estimated at 300-watts continuous, 
so that at a production level of 5 million kits per year, and assuming 10 flights per 
year, the power requirement per flight would be, say, 5 x 300 watts 1500 watts 
continuous, or an energy requirement of 1500 watts x 156 hours = 234 KWH. 
VI. 1.3 DETERMINATION OF NUIVIBER OF FLIGHTS FOR PILOT PLANT AND 
PRODUCTION 
A baseline assumption of 10 flights per year has been used, relative to an annual 
throughput of 1. 2 million kits. Increase of production to 5 million kits per year 
would be accommodated by increasing the number of separator stations on each 
flight. At present, no basis exists for assessing the production level required rela­
tive to customer needs (e. g., seasonal demand, storage limitations, number of 
different types of diagnostic kits required over a typical year, .etc.) Thus an essen­
tially linear output has been assumed. It is conceivable that a very few flights 'of 
very high output would be more economical, or necessary to meet customer orders. 
It is also possible that a high priority order could call for a special unscheduled 
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ISOENZYME THROUGHPUT ANALYSIS 
GEL PREPARATION PROCESS (GROUND) 
Filling time per Gel tube (25 cm tube) 1 hour 
Tube size 
Protein charge per tube 
Gel per tube 
Gel tubes req'd peryr (6 tubes x 10 fits)
Protein charge per yr (1 gr x 6 tubes x 10 fits) 
5-8 cm diam., 20 25 cm length 
I gram 
250-300 grams 
60 tubes 
60 grams 
ISOENZVME SEPARATION PROCESS (iN-SPACE) 
Gel tube dimensions m8 cm thm, 20-25 cm lengt 
Gel per year (60 tubes x 300 gr/tube)Gel tube volume 18 Kg (18,000 grams)962 cm 3 Protein charge (raw enzyme) per tubeIsoenzyme yield (from protein charge)Separated soenzyme (antigen) per tube 
1 gram10% 
100 mg 
FACI LITIES 
Gt reservoir (mixing & filling) Protein charge req'd per Fit (6 x 1 gram)Protein charge req'd per yr (6 grams x 10 fits) 6 grams60 grams 
Gel filling equip Operating time per Gel tube 24 hrs 
Gel tube freezing equipProtein charge storage equip
Protein charge fiing equip 
Operating time per flight
Flight duration (shuttle) No of separation cycles per flightNo. of Electrophoreis separators per flight 
156 hrs 
7 days6 (6 tubes output)
1 
No. of flights/yr 10 
No of Gel tubes outputlyr (10 f its x 6 tubestyr) 60 tubes 
Antigen output per tube 100 mg 
Antigen output per fit (6 fits x 100 mg) 
Antigen output per yr (600 mg/fit x 10 fits) 
600 mg 
6000 mg 
FACILITIES 
Electrophoresis unit (1-25 cm tube)Gel tube storage unit (freezer) 
Buffer reservoir and pump 
Chamber cooling system (reservoir, circulator pump, cooler) 
Electrophoresis unit power supply and controls (constant current) 
ISOENZYME/ANTIBODY PREPARATION PROCESS (GROUND) 
Antigen input per year (from space process) 600 mg per fit (1 tube)
 
No. of flightsiyr (1 type per flight) 10
 
Gel slices per 20-25 cm tube 100
 
Aqueous buffer/antigen solution 30% antigen, 70% buffer (by wt)

Antigen yield (powder) from buffer solution 100%
 
No. of horses req'd for 600 mg available per fit 8-10 (80-100 for 10 fits per yr)
 
Horse shots req'd per yr per type (antigen) 60-70 mg per horse
 
Horse initial shots required (per horse) 15 mg (5 mg per week)
 
Horse booster shots required (par horse) 5 mg, once per month
 
Horse blood donation frequency Once per 2-4 weeks
 
Blood antiserum donation per hone per month 500 milliliters
 
Gamma globulin fraction per milliliter of horse blood 2mg
 
Gamma globulin fraction per horse Pt month 1000 mg
 
Gamma globulin fraction (isoenzymes) quantity per kit I milligram
 
No. of kits of each type per year 96,000 - 120,000
 
(12 mo x c1000 mg/mo x 8-10 horses) 
No. of kit types 10 
Diagnostic kits output per year (10 types x 96 K-120K) 0 96M - 1.2M 
FACILITIES 
Gel tube removal, shcing & selection (6 tubes/fit x 10 fIts/yr = 60 tubes per year)
 
Antigen ginnd, buffer, freeze dry, injection preparation (80-100 hones x 14 injections/horse/yr = 1100-1400 hypos'/yr)
 
Horse antiserum prep (horse farm) 80-100 hones
 
Gammaglobulin fraction prep (1.2M kit doess/yr)
 
Diagnostic kit preparation, pack, ship (1.2M kits/yr)
 
Figure VI-1. Isoenzyme Space Product Throughput Analysis 
flight. In the meantime, the best basis appears to be to use the 10 flights per year 
(one to 5 flights per year for initial production) and to assume that the flexibility in 
size or number of separators can be used to accommodate any flight frequency re­
strictions. 
VI. 1. 4 DETERMINATION OF RESOURCES REQUIRED FOR PILOT PLANT AND 
PRODUCTION 
A summary of the production resource requirements is shown in Figure VI-2. Plant 
and equipment requirements are roughly estimated as shown in Figure VI-S. The 
The horse farm requirements are shown separately in Figure VI-4. Roughly, about 
100 overhead and 400 manufacturing personnel might be required, in full scale pro­
duction (Figure VI-5). 
VI. 2 ANALYSIS OF PRODUCTION COSTS 
A breakdown of the manufacturing costs by process step for an annual production of 
1. 2 million units is shown in Figures VI-6, VI-7, and VI-8. The unit cost of $2.49 
is roughly the same as used for the year 1992 in the financial forecast ($2.50). A 
figure of $6. 00 was used as unit cost in the early years when the selling price was 
high. 
VI2. 1 SHUTTLE/SPACELAB OPERATION COSTS AND RESOURCE COSTS 
Space operations costs at an annual production level of 1.2 million units are esti­
mated at $1292K (Figure VI-6). Most of this amount is for shuttle service charges 
as calculated in Figure VI-8. Linear extrapolation of these service charges to a pro­
duction level of 5 million units per year (1992) would give an annual space service 
charge of about $5 million, against annual sales of about $33 million. 
VI. 2.2. DEFINITION OF ADDITIONAL NON-SPACE PROGRAM COSTS 
The post-space process steps, for antibody growth, antibody processing and kit pre­
paration, account for about 40% of the unit manufacturing cost (Figure VI-6). 
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MATERIALS 
-Gel tubes, gels, proteins, buffers, tissue, sera, diagnostic kit 
materials, 
SERVICES 
Shuttle launch and support (NASA)
 
Product test (hospitals, clinics)
 
EQUIPMENT 
Preparative scale electrophoresis equipment (0-G) 
Gel tube preparation equipment 
Antibody preparation equipment 
Diagnostic kit preparation equipment 
FACILITIES 
Gel tube preparation Lab (production) 
Antigen preparation Lab (production) 
Launch and Return Facilities (Shuttle) (NASA) 
Antibody Growth Facility (Horse Farm) 
Diagnostic Kit preparation facility (production) 
Product Quality Control Lab 
SPECIAL MANPOWER SKILLS 
Biochemists and technicians
 
Product test and evaluation clinicians
 
Figure VI-2. Isoenzymes Production Resource Requirements Summary 
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1. 2M kits/yr. 5MW kits/yr. 
Gel Prep. facility 
50 x 50 ft. = 2,500 sq. ft. 
@'$100/sq. ft. 250K
 
+ Equip. lOOK
 
350K x 3 = 1,050K
 
Space Proc'g. Equip. 
2 facil @ $500K 1, 000K x 3 = 3, OOOK 
Horse Farm incl. Equip. 400K x 3 = 1, 200K 
Antibody Prep. Facility (Lease & improvement of existing facility) 
10 kits/hr. /oper. x 2,080 = 
20, 800 kits/yr. /oper. 
1.2M - 20,800 = 58 operators 
@ 50 sq. ft. /oper. =2,900 sq. ft. 
x 2 = 5,800 sq. ft. @ $100/sq. ft. = 580K x 3 = 1,740K 
Total 2,330K 6,990K 
Time Scale: 78 79 80 81 82. 83 84 86 86 87 88 89 90 
- 300 350 - - -Gel Preparation 250 100 - -
Space Facility 500 500 500 500 500 500
 
Horse Farm 400 400 400 
Antibody Prep 58G 580 580 
Total ($K) - 750 600 980 - - 1280 850 500 - 1480 500 
Cum - 750 1350 2330 2330 2330 3610 4460 4960 4960 6440 6950 6940 6940 
Deprec. @ 100/yr. 75 135 233 233 233 361 446 496 496 644 694 694 694 
Net P&E 675 1215 2097 2097 2097 3249 4014 4464 4464 5796 5796 5796 5796 
Figure VI-3. Estimate of Plant & Equipment for Isoenzyme Processing 
Basis: 150 horses stabled year-round 
for for 
100 horses 150 horses 
Facilities (Investment)
 
10K Fencing $ 10K
 
20K Land (20 acres @ 1K) 
10K Equipment (tractor, etc.) 
10K Accoutrements (bins, halters, etc.) 
@ $100/horse 

180K Barn (27, 000 sq. ft. @$10/sq. ft.) 
(150 stalls, 12x15 ft. incl. aisle) 
30K Caretakers Quarters (1, 000 sq. ft. 
@$30) 
50K Horses (150 x $500) 
$310K 

Operating Expenses
 
20K Hay (150 x $200) 

10K Straw (150 x $100) 

117K Grain (150 x $1168) 

90K Stable men and supervision 
10K Veterinarian 

90K Overhead (100% of Labor) 

$337K 

20K 
10K 
15K
 
270K 
30K 
75K 
$430K
 
30K 
15K 
175K 
135K 
15K 
135K 
$505K
 
include office 
(with 3-4 mo. 
quarantine and 
health inspection 
(20 lb/horse/day,
 
$50/ton) (1-2 lb/
 
day per hundred wt,
 
1000 lb horse
 
(10 lb/horse/day)
 
(4 lbs/horse/day,
 
$8/100 Ib)
 
(15 men @$9K/yr.)
 
(1 man per 10 horses)
 
(1/2 time, $30K/yr.)
 
Figure VI-4. Horse Farm Estimate 
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Isoenzymes Rough Estimate of 
No. of Personnel 
Sales (dollars) $33M 
Sales (units) 5M 
Engineering Expense iM 20 
Selling Expense 1. 6M 30 
Administration Expense 1. 5M 50 
Manufacturing Cost 15M 400 
Net Annual Investment 9M 
Total 500 personnel 
Figure VI-S. Approximate Resources for Operating Year 1992 
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Gel Prep-Pre-Space 
(1992) 
Annual Cost 
1992 
Unit Cost 
E st. 
1985 
Unit Cost 
Labor (tube filling, 60 tubes) 
Materials (Gels, supplies, protiens) 
Overhead (100% of Labor) 
$ 9K 
3K 
9K 
$ 21K $ 0.02 $ 0.20 
Space Processing 
Labor, Ground Ops. 10 flights 
Materials, mipc. 
Services, Shuttle (see estimate) 
Overhead (100% of Labor) 
100K 
25K 
1067K 
100K 
.08 
.03 
.89 
.08 
.50 
.21 
.89 
.50 
$ 1292K $ 1.08 $ 2.10 
Gel Processing-After Space 
Labor (see breakdown) 
Material 
Overhead (100% of Labor) 
$ 11. 1K 
3.0K 
11.1K 
$ 25.2K $ 0.02 $ 0.20 
Horse Farm 
Labor 
Overhead 
Material 
$ 90K 
90K 
157K 
$ 337K $ 0.28 $ 0.50 
Antibody Prep 
Labor (see breakdown) 
Overhead 
Material 
$ 174K 
174K 
60K 
$ 408K $ 0.34 $ 0.80 
Packaging Kits 
Labor (see breakdown) 
Overhead 
Material ($0. 15/kit) (cap, vial, package) 
$ 360K 
360K 
180K 
$ 900K $ 0.75 $ 1.50 
TOTAL $ 2983K $ 2.49 $ 5.30 
Figure VI-6. Estimated Unit Manufacturing Cost 
Isoenzyme Kit (Basis 1,200,000 kits/yr.) 
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Gel Processing Labor (post-space) 
Removal Gel I hr. 
Slice and Isolate 4 hrs. -
Grind and Solubilize 8 hrs, 
UV Analysis 16 irs. 
Combine fractions/freeze 8 hrs. 
37 hrs. per tube 
37 hrs. x 60 tubes x $5/hr. - $11,100 
Antibody Preparation (post-space) 
Prep Antigen into injectable form 20-hrs. 
Inject 10 horses/0 injections 80 hrs. 
Bleed 10 horses/20 bleedings 160 hrs. 
Separate serum 40 hrs. 
Fractionate Gamma Globulin 160 hrs. 
Quality Control-Gamma Globulin 40 hrs. 
Freeze Dry 40 hrs. 
Bind to Latex 40 hrs. 
580hrs. per tube 
580 hrs. x 60 tubes x $5/hr. = $174,000 
Kit Packaging (assume automated) 
1,200,000 kits 10 kits/hr. x $3/hr. =360K 
(fill and close vials, sterilize, label and package) 
Figure VI-7. Labor Breakdown for Isoenzymes Kits Prep 
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Basis 1. 2M kits/yr (1985) 
Up Transport Volume (10 fits/yr.) 
(0. 5M3 x $13,760/MS x 10) 
Annual Charges 
$ 68.8K 
Up Transport Weight 
(180 kg x $110/Kg x 10) 198. OK 
Energy 
(0.3 kw x 156 hrs. 
Crew 
x l0 x $40/KWH)* 18.7K 
(I man hr/day x 7 days x 10 x $6450/hr.) 451.5K 
Data Trans 
(None) 
Data Proc 
(None) 
Down Weight 
(180 kg x $180/kg x 10) 324. OK 
Ground Ops (Mech. Support) 
(0. SM3 x $1280 x 10) 6.4K 
Gnd Ops (Elec. Support) 
(None) 
Total Annual Charges $1067.4K 
* $40/KWH for production vs. $1, 721/KWH for R&D 
Figure VI-8. Calculation of Isoenzymes Production Space Charges 
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Expansion of existing facilities or building of new facilities would be required for full 
scale production, although initial production could, and probably would be performed 
in available space. The horse farm for antibody growth is costed as a new purchase 
(investment) but since sources of similar services already exist, an option would be 
to arrange for antibody growth as a purchased service (expense). The kit preparation 
facility is envisioned as an automated process to allow throughput of millions of kits 
per year with relatively few operators and high quality control standards. Quality con­
trol will be an important function for the business and continuous sampling and product 
testing will need to be conducted to ensure a high efficacy product which meets all 
industry and government standards 
VI. 2.3 ANALYSIS OF TOTAL PRODUCTION COSTS 
The selling price objective for the isoenzyme kits is to sell at the lowest possible unit 
price and thus to open up a product demand based on large scale diagnostic surveys. 
Thus all cost elements of the production sequence (Figure VI-6) require close scrutiny, 
and above all, detailed confirmation of their validity. The process steps are assumed 
to be very simple, repeatable steps, and the equipment used, including the space 
electrophoretic separators, are assumed to be relatively non-complex. These assump­
tions ,may not hold up under further investigation, 
For lack of a better basis, the yield from each process step is presently based on 
obtaining 100% of a given amount from each process cycle. Perturbations in process 
conditions (e. g. vibration levels during space processing) could cause reduced yields 
and thus change the unit manufacturing cost substantially. This is especially so, due 
to the high multiplier which is estimated between a gram of space-separated isoenzyme 
and the number of kits produced. For example, a variation of one gram in space product 
can cause a change in production of 200, 000 kits, which at $6. 00 per kit, is a variation 
in sales of $1.2 million. 
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VI. 3 ANALYSIS OF COST/VALUE 
The isoenzyme product exhibits a very good opportunity for profitability, based on the 
unit price and unit cost assumptions used. The high attractiveness and uniqueness of 
a successful product allows flexibility in establishment of the selling price, especially 
in the early years, and the high volume/small space production quantity gives a 
relatively low unit cost. 
VI. 3.1 DERIVATION OF GROSS MARGIN 
Gross margin, or the difference between unit manufacturing cost and selling price, 
for the baseline case is estimated at $6.00 - $2.50 = $3. 50 per unit in 1992. Other 
values of margin exist in preceding years, when the unit manufacturing cost and selling 
price are higher. (See Section IV Cash Flow Analysis). Gross margin allows for 
net profit and expenses other than shop cost (I.e., R&D, engineering, selling, 
administration, depreciation, and interest expenses and federal income taxes). 
This margin (Case B) gives a net income to sales of 21 per cent in 1992. 
VI. 3.2 IDENTIFICATION OF SIGNIFICANT COST/VALUE ASSUMPTIONS 
A key assumption in forecasting the business was that one or more isoenzymes of 
very high attractiveness for general diagnostic surveys would be discovered. This 
assumption supports the total market forecast of 50 million kits per year (1992). 
A fundamental assumption, of course, is that the isoenzymes of interest do exist, 
that they can be isolated successfully, and that the space environment is essential 
to the separation process. 
The R&D program assumes that the development of the gel electrophoresis separator 
for zero-G operation will not encounter major difficulties, and will be developed to 
prototype status after just a few shuttle flight experiments. 
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The space charges used are based on the BUS Phase III Model and are a major cost 
element in the forecast. Any changes in the basis for space charges will have a 
significant effect on the forecasted business viability, although the isoenzyme product 
appears to be relatively insensitive to space charges. 
VI. 3.3 SENSITIVITY ANALYSIS 
The "present value" of the product venture (discounted at 10%) has been used as a 
common measure for assessing the sensitivity of the venture to the estimates used 
for the various cost elements. Each of the 15 parameters used in the cash flow 
analysis was varied +10% and the financial forecast was calculated for each case, 
a total of 30 projections. The resultant present value in each case was then compared 
with the baseline case present value, giving the delta low.(-10%),and delta high (+10%) 
figures as shown in Figure VI-9. The parameters with the largest changes in present 
value for a 10% change in estimate are thus of most interest. The high impact 
parameters are plotted in Figure VI-10. Assuming linearity beyond the +10% point, 
a 40% reduction in unit price would cause a 4 x $3747K = $15M reduction in present 
value, enough to cause a negative present value for the venture. Similarly a 40% 
increase in the unit manufacturing cost could cause 4 x $2272K = $9M change in 
present value, not enough to cause a negative present value for the venture. In 
comparison, a much larger percentage change in the estimate of the total market or 
market share would be necessary to cause a negative present value. R&D costs, 
selling expense, administration expense, and engineering expense have a relatively 
small impact on the profitability of the venture. 
Space charges are a major element within unit manufacturing cost (about 43%). Thus 
changes in the basis for assigning space. charges would have a relatively significant 
effect on the profitability of the venture. 
The above sensitivity analysis provides a rough indication of parameter sensivitity. 
When desired, the particular effects of parametric changes can be studied in detail 
by running test cases with the INVEST program. 
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INVhbT INTERACTIVE NEW VENTURE EXA'-INATIaN AND SENSITIVITY TEST 
SENSITIVITY ANALYSIS OF CHANG3E IN PRESENT VALUE
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Fgure VI-9. Isoenzymes Parameter Sensitivity Data 
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Figure VI-10. Isoenzymes Parameter Sensitivity 
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